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2  K U R Z F A S S U N G  
Stammzellen sind Körperzellen, die sich durch symmetrische oder asymmetrische Teilung 
entweder unendlich vermehren, oder in verschiedene Nachkommen ausdifferenzieren 
können. Sie stellen die funktionellen Elemente für therapeutische Ansätze zur 
Krankheitsbehandlung dar und finden in den verschiedensten Bereichen der 
Stammzelltransplantation und bei der Herstellung von Geweben durch „Tissue 
Engineering” ihren Einsatz. Für diese Anwendungen sind die Charakterisierung, sowie die 
Entwicklung von Methoden zur Definition und Trennung von Stamm- und Vorläuferzellen 
notwendig. Mehrere Studien haben über die Existenz dermaler multipotenter 
Stammzellen berichtet, ohne allerdings deren genaue Lokalisation in der Dermis 
nachweisen zu können. Ziel dieser Arbeit war es daher, Stammzellen in der humanen 
Haut zu identifizieren. Mittels Immunofluoreszenz-Färbungen von Gefrierschnitten 
humaner Vorhaut und Analyse am konfokalen Laser-Scanning Mikroskop konnten wir 
durch Kombination verschiedenster Oberflächenmarker wie CD34, CD133, oder CD318, 
die für Stammzellen beschrieben wurden, tatsächlich Zellen identifizieren, die solche 
Marker exprimieren. Der Stammzellcharakter dieser Zellen wird in funktionellen 
Experimenten noch zu prüfen sein. Der Erhalt primitiver, aktiv zirkulierender 
Stammzellen aus einem einfach zugänglichen Gewebe wie der Haut könnte die Effizienz 
vieler aktueller Therapien erheblich verbessern.  
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3  A B S T R A C T  
The commonly used criteria that define stem cells are sustained proliferation, 
multipotency and self-renewal. They are the functional elements of reparative medicine 
and tissue engineering. For potential therapeutic utility, the characterization and 
establishment of methods to separate defined populations of stem and progenitor cells of 
other than the commonly used sources is of great interest. For this reason we 
investigated human skin for the presence of stem cells of different lineages. Compared to 
other stem cell sources, skin is easy accessible, and it contains stem cells which can 
differentiate into tissues of all three germ layers. Furthermore, the extraction of small 
amounts of skin tissue is simple and without any risk, and can be pursued into 
adulthood. Despite the fact that multipotent dermal stem cells have been described, so 
far to our knowledge, no one has traced these cells in the dermis. Using multi-colour 
immunofluorescence staining of cryostat sections of human foreskin with subsequent 
analysis with confocal laser scanning microscopy, we demonstrate that subsets of 
putative stem/progenitor cell populations can be characterized by combination of various 
cell surface markers, such as CD34, CD133 or CD318. The availability of pure, primitive, 
actively cycling stem cells from an easily accessible source, such as skin, may improve 
the efficiency of a number of gene therapy protocols.  
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4  A B B R E V I A T I O N S  
7-AAD 7-amino-actinomycin D 
Ab Antibody 
AF Alexa Fluor 
APC Allophycocyanine 
ß-gal ß-galactosidase 
BM Bone marrow 
BSA Bovine serum albumin 
CD Cluster of differentiation 
CLA Common leukocyte antigen 
CLP Common lymphoid progenitor(s) 
CLSM Confocal laser scanning microscopy 
DDT Dichloro-diphenyl-trichloroethane 
DEPC Diethylpyrocarbonate 
DMSO Dimethylsulfoxide 
DNA Desoxyribonucleic acid  
DNase I Desoxyribonuclease I 
E Erythrocyte 
EDTA Ethylenediaminetetraacetic acid 
FACS Fluorescence-activated cell sorter/sorting 
FCS Fetal calf serum 
FITC Fluorescein-isothiocyanate 
GB Gitschier’s buffer 
GMP Myelomonocytic progenitor(s) 
HFSC Hair follicle stem cell(s) 
HLA Human leukocyte antigen 
Hox Homeobox 
HPRT Hypoxanthine guanine phosphoribosyltransferase  
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HSC Hematopoietic stem cell(s) 
Ig Immunoglobulin 
K14 Keratin 14 
Lin Lineage 
LT-HSC Long-term hematopoietic stem cell(s) 
mAb Monoclonal antibody 
Meg Megakaryocyte 
MEP Megakaryocyte-erythrocyte progenitor(s) 
Min Minute(s) 
MPP Multipotent progenitor(s) 
mRNA Messenger ribonucleic acid 
MSC Mesenchymal stem cell(s) 
NSC Neural stem cell(s) 
O/N Overnight 
PAL-E Pathologische Anatomie Leiden-Endothelium 
PBS Phosphate-buffered saline 
PCR Polymerase chain reaction 
PE Phycoerythrin 
PFA Paraformaldehyde 
RCF Relative centrifugal force 
RNA Ribonucleic acid  
RT Room temperature 
RT-PCR Reverse transcriptase polymerase chain reaction 
SC Stem cell(s) 
Sca-1 Stem cell antigen-1 
Sec Second(s) 
SKP Skin-derived precursor(s) 
SP Side population 
ST-HSC Short-term hematopoietic stem cell(s) 
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5  I N T R O D U C T I O N  
5 . 1  S T E M  C E L L S  
Stem cells have been defined as populations of cells that undergo symmetric and 
asymmetric divisions to either self-renew or differentiate into multiple kinds of 
differentiated progenya 1-3. Research in the stem cell field started out of findings by the 
Canadian scientists HTErnest A. McCulloch TH and HTJames E. TillTH in the HT1960sTH, who 
demonstrated the presence of self-renewing cells in mouse bone marrow (BM) 4. 
Stem cells can be distinguished from each other based on the tissue of origin, their bias 
in differentiation ability, the stage of development at which they exist, and the genes 
they express 2 (T A B L E  1 ). 
Stem cells are basically divided in two main categories: HTembryonic stem cells TH and HTadult 
stem cells TH. The abilities of unlimited expansion and pluripotency make embryonic stem 
cells a potential source for regenerative medicine and tissue replacement after injury or 
disease 3;4. Adult stem cells or somatic stem cells are undifferentiated cells and reside in 
peripheral blood and nearly every tissue, including the brain, BM, kidney, epithelia of the 
digestive system, skin, retina, muscles, pancreas, and liver. Adult stem cells are able to 
produce identical daughter cells during a relatively large number of cell divisions. This 
feature is often referred to as self-renewal or clonogenicity. Another property of adult 
stem cells is their ability to give rise to precursors of mature, and then terminally 
                                                 
TP
a
PT TST AG E S  O F  D I F F E R E N T I A T I O N  P O T E N T I AL  O F  A  S T E M  C E L L T 
T O T I P O T E N C Y T Tthe fertilized oocyte forms the embryo and the trophoblast of the placentaT 
TPL U R I P O T E N C Y T embryonic stem cells differentiate into cells of all three germ layers: endoderm, ectoderm and 
mesodermT 
TMU L T I P O T E N C Y T Tmost tissue-based stem cells produce a limited range of differentiated cell lineages 
appropriate to their location 
TOL I G O P O T E N C Y T Tcells, such as epidermal stem cells, that can contribute to a more restricted subset of cell 
lineages usually within a single tissueT 
TUN I P O T E N C Y T Tability to generate one single cell typeT 
T A B L E  1 .  T I S S U E - S P E C I F I C  S T E M  C E L L S .    
E C T O D E R M  M E S O D E R M  
Epidermal stem cells 
Neural stem cells 
Neural crest stem cells 
Hair follicle stem cells 
Hematopoietic stem cells 
Mesenchymal stem cells 
Umbilical cord blood stem cells 
Umbilical cord matrix stem cells 
Cardiac muscle stem cells 
Skeletal muscle stem cells 
Multipotent adult precursor cells 
E N D O D E R M  G e r m  C E L L S  
Pancreatic islet stem cells 
Hepatic oval stem cells 
Primordial stem cells 
(adapted from Cai et al. 2) 
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differentiated cells with specified morphological characteristics and function. In mature 
tissues, adult stem cells play a crucial role in maintaining local homeostasis by replacing 
dead or damaged cells as well as in the process of tissue remodeling. Many adult stem 
cells may be better classified as progenitor cells, due to their limited capacity for cellular 
differentiation. Specific multipotent or even unipotent adult progenitors may have 
potential utility in regenerative medicine. They have mainly been studied in HThumansTH and 
HrodentsH 3;5-8.  
5 . 2  S T E M  C E L L  P L A S T I C I T Y  
Stem cell plasticity refers to the ability of adult stem/progenitor cells to acquire mature 
phenotypes that are different from their tissue of origin 9. However, most studies 
published so far have not definitively proved that the greater potency of adult stem cells 
can be ascribed to a single cell that can differentiate into the tissue of origin and one or 
more additional tissues. Some investigators have suggested that transdifferentiationTPFbFPT of 
stem cells or cell-cell fusion underlies these events and therefore care should be taken in 
the interpretation of data. Beyond the ability to differentiate into lineages of blood cells, 
hematopoietic stem cells (HSC) might have sufficient plasticity to give rise to other 
nonhematopoietic cells, such as muscle cells, neurons, hepatocytes, adipocytes, 
osteoblasts, and others. HSC and multipotent progenitors (MPP) can be mobilized into 
the circulation following treatment with a variety of natural or molecularly engineered 
cytokines, chemokines, and adhesion molecule antagonists 4;10-15. 
5 . 3  S T E M  C E L L  N I C H E  
Stem cell niches are composed of microenvironmental cells that nurture stem cells and 
enable them to maintain tissue homeostasis. An appropriate dialog occurs between stem 
and niche cells in order to fulfil lifelong demands for differentiation and maintenance of 
stem cells. Niche cells provide a sheltering environment that isolates stem cells from 
differentiation stimuli, apoptotic stimuli, and other stimuli that would challenge the stem 
cell reserves. The niche also safeguards against excessive stem cell proliferation that 
could lead to cancer. Stem cells proliferate periodically to produce progenitor or transit 
amplifying cells that are committed to produce mature cell lineages. Maintaining a 
balance of stem cell quiescence and activity is a hallmark of a functional niche 7;16;17. 
                                                 
TP
b
PT T R AN SD I F F E R E N T I AT I O N T describes the conversion of a cell of one tissue lineage into a cell of an entirely 
distinct lineage, with concomitant loss of the tissue specific markers and function of the original cell type 
together with acquisition of markers and function of the transdifferentiated cell 3. 
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5 . 4  H E M A T O P O I E T I C  S T E M  C E L L S  
HSC are the best studied adult stem cells and the most primitive cell type in the 
hematopoietic lineage 15. They self-renew for lifetime and give rise to short-term 
reconstituting subsets of HSC, with limited self-renewal capacity, and then to MPP that do 
not self-renew.  
Differentiation progresses with segregation of myeloid and lymphoid lineages through the 
generation of common myeloid progenitors (CMP) 18 and common lymphoid progenitors 
(CLP) 19. Both CLP and CMP undergo further lineage segregation, with CMP giving rise to 
myelomonocytic progenitors (GMP) and megakaryocyte/erythrocyte progenitors (MEP) 
that separate granulocyte and macrophage production from red blood cell and blood cell 
production 15;18;20-22. This model states that only the most primitive long-term 
reconstituting subsets of HSC (LT-HSC) self-renew for life and give rise to short-term 
reconstituting subsets of HSC (ST-HSC), with limited self-renewal capacity, and then to 
MPP that do not self renew 23-25. In the mouse, multipotent hematopoietic activity is 
contained in a small fraction of the BM that lacks expression of mature hematolymphoid-
associated cell-surface markers (lineage markers) and displays high levels of the stem 
cell-associated markers c-Kit and Sca-1 (Lin-c-Kit+Sca-1+ or KLS). The KLS fraction can 
be further subdivided into functionally distinct subpopulations based on the expression 
levels of different markers, such as Thy1. Loss of Thy1 and gain of Flk2 in the KLS 
fraction correlates with decreased self-renewal ability and increased proliferation. It has 
been reported that in mice, Flk2-expressing KLS cells might not be fully multipotent 
because they failed to generate significant Megakaryocyte (Meg) and Erythrocyte (E) 
progenies (MegE potential) in the assays used in those studies. Conclusions from those 
reports suggested that early progenitor populations might sequentially lose lineage 
potential as they differentiate from LT-HSC, starting with loss of MegE potential. 
Recently, it has been demonstrated, that Flk2+ ST-HSC and MPP retain MegE potential at 
the population and clonal levels in vivo. These results indicate that Flk2 expression by 
early progenitors is not at the expense of full multipotency and support a model of 
hematopoietic development with segregation of myeloid and lymphoid lineages from 
multipotent progenitors, loss of lineage potential occurs later during differentiation into 
the oligolineage-commited progenitor populations 26 (F I G .  1 . ). 
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It is possible to distinguish among HSC, progenitors, and more mature cells within the 
CD34P+P population by their different patterns of expression of other markers. For 
example, the CD38 antigen is expressed at intermediate to high levels on more than 
90% of CD34P+P cells from most sources of hematopoietic cells. CD34P+PCD38P-P cells have the 
ability for sustained multilineage hematopoietic reconstitution after transplantation into 
immunodeficient mice 22. Other markers that are absent or only weakly expressed on 
HSC and primitive progenitor cells but highly expressed on certain types of lineage-
committed progenitor cells include CD33, CD71, HLA-DR, and CD45RA. These markers 
can be used to subdivide CD34P+P cells into lineage committed and multipotent fractions. 
There is also evidence for the existence of CD34P-P cells with HSC and lymphopoietic 
potential in human cord blood and adult hematopoietic sources. The phenotype of CD34P- P 
HSC has been characterized by the additional absence of CD38 and lineage-specific cell 
surface antigens as well as the expression of CD133 27.  
The term HSC has at times been used to include a miscellany of precursor cells ranging 
from multipotential self-regenerating cells to lineage-restricted progenitors with little 
capacity for self-generation. It is probable that the stem cells of other tissues also vary 
widely in their multipotentiality and proliferative capacity 28. 
5 . 4 . 1  T H E  H S C  N I C H E  
In adults, the majority of HSC reside in the BM, where they are intimately associated 
with mesenchymal cells that constitute the hematopoietic microenvironment and which 
produce stimulatory and inhibitory factors that regulate stem cell development. Bone and 
marrow are intrinsically linked with HSC, and their primitive progeny are located proximal 
to the endosteal surface of trabecular bone. Osteoblasts are required for this localization 
F I G U R E  1 .  B L O O D  L I N E A G E  D E V E L O P M E N T .  As LT-HSC 
differentiate into ST-HSC and then to MPP, they 
progressively lose their self-renewal ability, increase their 
proliferation, and change their gene expression programs 
to leave the stem cell niche and undergo lineage 
differentiation while remaining multipotent. The lymphoid-
primed multipotent progenitors (LMPP) represent a more 
committed subset of MPP. (adapted from Eckfeldt et al. 1) 
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7;11;16;17. The niche’s milieu allows it to retain stem cell daughters, but expel terminally 
differentiating daughters 7. Its complex environment comprises many different cell types, 
which together secrete a specialized extracellular matrix. The effects of these supporting 
cells are mediated through specific molecular interactions, some of which could be used 
to promote HSC expansion in vitro 21. Of particular interest for possible clinical 
applications of stem cell expansion are genes that (i) encode transcription factors (e.g. 
HOXB4TP, GATA1/2TP, SCL/TAL1TP), (ii) signaling molecules (e.g. WNTTP, NotchTP, Ang-1TP), and (iii) 
genes that regulate the cell cycle (e.g. p18TP, p21, p27P). 
5 . 4 . 2  S I D E  P O P U L A T I O N  C E L L S  
In the population of hematopoietic cells are cells that manifest a specific profile with the 
use of Hoechst 33342 dye. These are so called side population cells and, when isolated 
from BM, they differentiate into various types of cells different from hematopoietic 
lineages. Side population cells have been detected in many tissues (e.g. small intestine, 
skeletal muscle) and in different species including humans. BM-derived side population 
cells are highly enriched for long-term repopulating cells, engraft in irradiated recipients 
and show multi-lineage reconstitution. In skin, cells with a side population phenotype are 
localized in the epidermis, with a few in the dermis and express high levels of α6-
integrin, β1-integrin, Sca-1, Keratin 14 and 9 and low levels of E-cadherin, CD3 and 
CD71 3;15;27;29. 
5 . 5  M E S E N C H Y M A L  S T E M  C E L L S  
Mesenchymal stem cells (MSC) can give rise to BM stroma, bone, cartilage, tendon, fat, 
and, at least in rodents, skeletal muscle 30. Their origin is either the cambium layer of 
periosteum or BM; furthermore muscle, fat, and synovium provide a limited source. MSC 
have a large capacity for self-renewal while maintaining their multipotency. MSC are the 
basic cellular unit of embryologic bone formation. Secondary bone healing mimics bone 
formation with proliferation of MSC, and their subsequent differentiation into components 
of fracture callus. Bone regeneration can be achieved by autologous transplantation of 
MSC, combined with strategies of osteogenesis, osteoinduction, osteoconduction, and 
osteopromotion. However, the capacities of cells to HproliferateH and HdifferentiateH are 
known to decrease with the age of the donor, as well as the time in culture. Although 
these cells do not have hematopoietic differentiation potential, they might be able to 
support HSC expansion in vitro or may be used to increase engraftment of HSC in vivo. 
MSC are known to derive from individual clonogenic cells, termed colony-forming unit-
fibroblasts, which have fibroblastic appearance, characteristic prominent nucleoli, but are 
extremely rare in human peripheral blood. In the presence of osteogenic stimuli such as 
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HTascorbic acid TH, HTinorganic phosphateTH and HTdexamethasoneTH, MSC differentiate into 
HTosteoblastsTH. Addition of HTtransforming growth factor-betaTH differentiates MSC into 
HTchondrocytes TH 7;31-34. 
A mesenchymal-related cell type, termed multipotent adult progenitor cell, was isolated 
from humans, rat and mouse, which grows on a fibronectin-coated surface. Multipotent 
adult progenitor cells could proliferate without senescence and differentiated into 
mesodermal, neuroectodermal and endodermal cell types 35-37. Furthermore, CD271, 
CD140b, CD340, CD349 and many more molecules were described as MSC-specific. 
These markers are suitable for the prospective isolation of highly purified BM MSC, which 
can be used as an improved starting population for transplantation in various diseases 38. 
Most recently, clonal, multipotent MSC have been isolated from human postnatal dermal 
tissue. The progeny of a single MSC could be differentiated into adipogenic, osteogenic, 
and myogenic lineages 39. 
5 . 6  T H E  H E M A N G I O B L A S T  
Endothelial and hematopoietic cells arise in close spatial and temporal association from a 
common mesodermal progenitor in the yolk sac, the hemangioblast 40. It has been 
conceptually accepted that the hemangioblast is a transient cell population, present only 
during embryogenesis, but recent studies in postnatal mice and humans provide evidence 
that the hemangioblast is also present in the postnatal stage and that adult HSC or their 
progenitors have a similar capacity as they can also contribute to the maintenance and 
repair of the vascular systems. For example, human CD133+ cells from granulocyte 
colony stimulating factor mobilized peripheral blood can differentiate into both 
hematopoietic and endothelial cells in cultures. Further characterization of the 
hemangioblast, both embryonic and postnatal, will be critical for a better understanding 
of the molecular events involved in hematopoietic and endothelial cell differentiation 41;42. 
5 . 7  T H E  F I B R O C Y T E  
Fibrocytes are BM-derived mesenchymal progenitors that coexpress HSC antigens, 
markers of the monocyte lineage and fibroblast products. These cells contribute to the 
new population of fibroblasts and myofibroblasts that emerge at the tissue site during 
normal or aberrant wound healing, in ischemic or inflammatory fibrotic processes, and as 
part of the stromal reaction to tumor development. Fibrocytes were found to express 
CD34, CD45 and several markers of the monocyte lineage, such as CD14. Recent data 
suggest that fibrocytes mature from an immature subpopulation of CD14+ peripheral 
blood mononuclear cells, which can differentiate into a number of cells different from 
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macrophages and dendritic cells. This subpopulation may represent an intermediate 
stage of differentiation of precursors of the monocyte lineage into mature fibroblasts and 
myofibroblasts at the tissue sites. Fibrocytes can be distinguished from circulating or 
tissue-resident MSC/multipotent mesenchymal stromal cells, because the latter cells 
express fibroblast products but are CD90+ and do not express CD34 or CD45. Human 
MSC can express CD34 and CD45, but remain negative for monocyte markers. Mature 
fibrocytes produce more collagens and fibronectin than fibroblasts, express the 
myofibroblast marker α-smooth muscle actin (α-SMA), and downregulate expression of 
CD34 and CD45 43. 
5 . 8  T H E  C E L L  S U R F A C E  P R O F I L E  O F  H U M A N  
H S C  
There are several markers whose expression changes at different rates as primitive 
hematopoietic cells differentiate. By targeting various combinations of markers, it has 
become possible to subdivide this functionally heterogeneous mixture of cells into more 
homogeneous subpopulations. 
5 . 8 . 1  L I N E A G E  M A R K E R S  
One distinguishing characteristic of stem cells is the absence of differentiation markers. 
In the HSC field these markers have been summarized as lineage markers (Lin). Lack of 
expression of a number of Lin markers, which include all of the mature hematopoietic cell 
types (T cells, B cells, natural killer cells, monocytes, and granulocytes), can be used to 
distinguish immature cells from the more abundant differentiated cells in most 
populations of hematopoietic cells. Selection of LinP-P cells typically gives a 20- to 500-fold 
enrichment of HSC depending on the combination of Lin markers used. Examples of the 
Lin markers commonly used to isolate human LinP-P cells are Glycophorin A, CD2, CD3, 
CD4, CD8, CD14, CD15, CD16, CD19, CD20, CD38, CD56, and CD66b. MSC are LinP-P for 
osteoblast, chondrocyte, and muscle markers; neural stem cells are negative for 
astrocyte, oligodendrocyte, neuronal, peripheral neuron, mesenchymal markers and 
Schwann cells; and embryonic stem cells are LinP-P for ectodermal, endodermal, and 
mesodermal markers 2;15;22.  
5 . 8 . 2  S T E M / P R E C U R S O R  C E L L  M A R K E R S  
5 . 8 . 2 . 1  C D 1 3  
CD13 (aminopeptidase N, gp150) is a type II integral membrane protein composed of 
967 amino acids, and expressed on the cell surface as a homodimer. The protein is 
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expressed during hematopoiesis at several different stages of myeloid differentiation and, 
like CD33 and CD123, on long-term repopulating cells from human cord blood and BM. 
Under steady state conditions, macrophages, myelomonocytes, interdigitating dendritic 
cells, immature mast cells, granulocytes, some large granular lymphocytes, fibroblasts, 
osteoclasts, perineurium of peripheral nerves, central nervous system synapses, 
endothelial cells, placenta, renal proximal tubules, prostate secretory cells, small 
intestine, and bile duct canaliculi are anti-CD13 reactive. When expressed on CD34P+Pc-kit P+ P 
cells, it becomes a marker of a progenitor cell population that includes mast cell, 
monocyte and mast cell/monocyte (bipotential) precursors. CD13 autoantibodies are 
strongly associated with chronic graft versus host disease after BM transplantation 44;45. 
5 . 8 . 2 . 2  C D 1 4  
CD14 [lipopolysaccharide (LPS) receptor, monocyte differentiation antigen] is a pattern 
recognition receptor that detects antigenic molecules on the surface of bacteria 
(lipoteichoic acid on gram positive, LPS on gram negative), myobacteria (glycolipids),  
and fungi (mannans), as part of the innate immune system. A soluble form of this protein 
is secreted by liver cells and monocytes; in low concentrations it confers LPS-
responsiveness to cells which are otherwise CD14 negative. CD14 is detectable on 
macrophages/monocytes, granulocytes, Langerhans cell-like cells, dendritic cells and B 
cells 44;46;47. Circulating CD14+CD34low cells, but not CD14+CD34- cells, proliferate in 
response to stem cell growth factors, and exhibit clonogenicity and multipotency, as 
shown by their ability to differentiate not only into endothelial cells, but also into 
osteoblasts, adipocytes, or neural cells. The use of CD14+CD34low cells, which exhibit both 
phenotypic and functional features of stem cells, may be useful in improving cell-based 
therapies of vascular and tissue damage 48. 
5 . 8 . 2 . 3  C D 3 1  
CD31 [platelet endothelial cell adhesion molecule, (PECAM-1)] belongs to the 
immunoglobulin superfamily, and is a cell adhesion molecule that plays a key role in 
leukocyte trafficking across endothelium and removal of aged neutrophils from the body. 
It may mediate the signal-transduction pathways in spermatozoa and acts as a minor 
histocompatibility antigen in HLA-identical stem cell transplantation. CD31 is a superior 
marker for angiogenesis and can detect vascular endothelium associated antigen. 
Furthermore, it has been used to measure angiogenesis, which reportedly predicts tumor 
recurrence. The CD31 molecule appears on endothelial cells (at cell junctions) including 
glomeruli, alveolar wall capillaries, hepatic, lymphatic and splenic sinuses, platelets, 
megakaryocytes, monocytes, macrophages, Kupffer cells, osteoclasts, granulocytes, T 
cells, natural killer cells, plasma cells, fibroblasts, brown fat, trophoblasts and 
spermatozoa. CD31 and CD34 can be used as markers for myeloid progenitor cells that 
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recognize different subsets of myeloid leukemia infiltrates (granular sarcomas). CD31 has 
been used as a marker for benign and malignant human vascular disorders, and myeloid 
leukemia infiltrates in normal BM 44;49;50.  
5 . 8 . 2 . 4  C D 3 4  
CD34 was the first differentiation marker to be recognized on primitive human 
hematopoietic cells and is still the most commonly used marker to obtain enriched 
populations of human HSC and progenitors for research or clinical use. Cell surface 
expression of this protein has become the distinguishing feature used as the basis for the 
enumeration, isolation and manipulation of human HSC, because CD34 is downregulated 
as cells differentiate into more mature cells. Human and murine CD34 homologues are 
highly conserved in their protein coding regions. The cytoplasmic domains of the human 
and mouse proteins share 90% amino acid identity, the transmembrane and C-terminal 
regions of the extra-cellular domains are also well conserved, with 73-82% amino acid 
identity. The majority of human cells capable of producing multilineage hematopoietic 
engraftment in myeloablated recipients express CD34. But even in a highly purified 
population of CD34P+P cells (>90%), the frequency of cells possessing progenitor activity is 
typically <20% and the frequency of HSC is much lower (<0.1%). CD34 is expressed by 
dendritic interstitial cells, dermal dendrocytes, endometrial stroma, endoneurium, 
fibroblasts in breast, hair endothelial cells of blood vessels, endothelial cells of some 
lymphatics, fibrocytes, hematopoietic progenitor cells (pluripotent and erythroid-, 
lymphoid- and monomyeloid committed cells), follicle cells, lymphocyte (B and T) 
precursors, neural stem cells in the central nervous system, perivascular stroma, 
umbilical cord blood; but also outside the hematopoietic system on vascular endothelial 
cells and some fibroblasts (e.g. breast fibroblasts and vascular adventitial fibroblastic 
cells in stomach) 15;22;27;44;45;49-52. 
5 . 8 . 2 . 5  C D 4 5  
CD45 [common leukocyte antigen (CLA), T220 and B220 in mice] is a protein tyrosine 
phosphatase located in certain hematopoietic cells.  Different subsets of hematopoietic 
cells express different CD45 isoforms due to variable exon splicing, which can change in 
response to cytokines: CD45RA (naive/resting T cells, medullary thymocytes), CD45RO 
(memory/activated T cells, cortical thymocytes). CD45 is an essential regulator of T and 
B cell antigen receptor-mediated activation, and also required for thymic selection. 
Mutations with loss of CD45 cause severe combined immunodeficiency with a defect in 
cell function or development, lymphopenia, and deficiency in humoral and cell-mediated 
immunity. CD45 is expressed by hematopoietic cells (including monocytes, macrophages, 
mast cells) except mature red blood cells and their immediate progenitors, platelets and 
megakaryocytes; dendritic cells, fibrocytes, thymus (medullary thymocytes) 44;50. 
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5 . 8 . 2 . 6  C D 9 0  
CD90 is a 25-35 kDa glycosylphosphatidylinositol-binding glycoprotein expressed on 
fibroblasts, human BM and cord blood CD34P+P hematopoietic progenitor cells 53. 
Furthermore, it is widely used as a mouse HSC marker (Thy-1). CD90P+P cells from 
cultured neonatal normal human epidermal keratinocytes show higher proliferation and 
colony-forming abilities than CD90 P-P cells and, thus seems to be a marker for human 
keratinocyte stem cell-enriched populations in cultured keratinocytes. CD34P+PCD90P+P cells 
include HSC that serve as autologous grafts to replace the BM in patients with 
malignancies 44;54. 
5 . 8 . 2 . 7  C D 1 1 7  
HSC and progenitor cells express receptors for hematopoietic growth factors that are 
responsible for regulating their survival and proliferation, although the expression of 
many of these (e.g. receptors for IL-3, GMCSF, and IL-6) is upregulated as they 
differentiate into late precursor cells and mature blood cells. One exception is CD117 (c-
kit), the receptor for stem cell factor. CD117 mediated signal transduction is critical for 
the normal development and survival of haematopoietic progenitor cells (expressed on 
~2/3 of CD34P+P cells), mast cells, interstitial cells of Cajal (intestinal pacemaker cells), 
melanocytes and germ cells. Upon differentiation, CD117 expression is lost with the 
exception of mast cells, melanocytes and interstitial cells of Cajal 55. However, the 
expression level of CD117 on CD34P+P cells is usually high enough to allow its use in 
hematopoietic cell isolation methods 27;44;45. 
5 . 8 . 2 . 8  C D 1 3 3  
Other selection markers for human hematopoietic cells have been identified with 
expression patterns that overlap with, but are not identical to, those of CD34. One such 
marker is CD133 (AC133, Prominin-1) – a member of the prominin family gene products. 
CD133 was first described as a marker for human HSC and has recently been proposed 
as a universal marker for tissue stem/progenitor cells. It is expressed on a majority of, 
but not all, CD34P+P cells. These include immature progenitors, monocyte/granulocyte 
progenitors and some erythroid progenitors. It also appears to be expressed on CD34P- P 
HSC identified in human cord blood. Furthermore, CD133 is expressed on neural and 
endothelial stem cells, other primitive cells such as retina, villous and extravillous 
cytotrophoblasts, and syncytiotrophoblasts 15;27;44;51;52;56-58. 
5 . 8 . 2 . 9  C D 3 1 8  
CD318 (CUB-domain containing protein 1, CDCP1), has an expression pattern on adult 
human BM cells similar to that of CD133. It is expressed on HSC subsets, epithelial cells, 
and on cells with a phenotype reminiscent of MSC and neural cells. It is not expressed on 
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mature blood cells and was originally identified as a gene that is over-expressed in 
colorectal tumors and the K562 erythroleukemia cell line. The expression of CD318 on 
human hematopoietic cells is restricted to a subset of CD34+ cells including those with 
NOD/SCID repopulating activity, CD34P+PCD38P-P BM stem/progenitor cells, but not mature 
peripheral blood cells. Similar to CD34 and CD133, CD318 may thus be useful for the 
enrichment of human HSC and progenitor cells, but not for their discrimination. 
Furthermore, CD318 is unique in its property to recognize cells with phenotypes 
reminiscent of mesenchymal and neural progenitor cells 27;59. 
5 . 8 . 2 . 1 0  T H E  S I G N A L L I N G  L Y M P H O C Y T E  A C T I V A T I O N  M O L E C U L E  ( S L A M )  F A M I L Y  
O F  R E C E P T O R S  
The location and identity of differentiated cells are often defined by the differential 
expression of individual families of cell surface receptors. Thus, it is necessary to use 
complex combinations of markers to purify HSC. SLAM family receptors, including CD150, 
CD244, and CD48, are differentially expressed among hematopoietic progenitors in a way 
that correlates with progenitor primitiveness. The SLAM family is a group of 10-11 
surface receptors that regulate the proliferation and activation of lymphocytes. While the 
SLAM family is very well-investigated in the murine system, less is known about these 
proteins in the human system 16;60-62. 
5 . 9 . 2 . 1 0 . 1  C D 1 5 0  
CD150 is 4- to 17-fold upregulated in HSC as compared to multipotent hematopoietic 
progenitors and CD45P+P BM cells. 
5 . 9 . 2 . 1 0 . 2  C D 2 4 4  
CD244 is differentially expressed among HSC and progenitors, thus, HSC are CD244P-P, 
whereas some multipotent hematopoietic progenitors are CD244P+P. 
5 . 9 . 2 . 1 0 . 3  C D 4 8  
CD48 is a ligand for CD244 and expressed at significantly higher levels on CD45P+P cells as 
compared to HSC, or multipotent hematopoietic progenitors. CD48 is expressed by 
restricted B lineage and myeloerythroid lineage progenitors. 
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5 . 9  S K I N  
As the skin is the largest and most accessible organ, it provides an attractive target for 
therapeutic gene repair. Skin is composed of three primary layers: a multilayered 
epidermis of ectodermal origin, the underlying dermis of mesodermal origin, and the 
hypodermis (subcutaneous adipose layer, F I G .  2 ). The epidermis can be subdivided into 
the following strata: corneum, lucidum, germinativum, spinosum and basale. It consists 
of a HTstratified TH HTsquamousTH HTepitheliumTH composed of keratinocytes, associated hair follicles, 
sebaceous glands and sweat glands. The predominant cell type in the epidermis is the 
HTkeratinocyteTH. Stratification of the epidermis commences during embryonic development 
and is a process that continues to occur throughout the life of the organism. The dermis 
contains a number of structures including blood vessels, nerves, HThairTH follicles, HTsmooth 
muscleTH, HTglandsTH and HTlymphatic tissueTH. Additionally, it contains fibroblasts secreting 
collagen, elastin and ground substance providing support and elasticity of the skin. The 
dermal papillary layer is outermost and extends into the epidermis to supply it with 
nutrients. The dermal reticular layer is denser and is continuous with the hypodermis. 
The hypodermis consists of a network of collagen and fat cells. Normal skin contains 
BM–derived cells (such as epidermal Langerhans cells, dermal dendritic cells, 
macrophages, mast cells, and T cells) that are involved in host defence and inflammatory 
processes, including wound healing 3;63. 
Significant progress has been made in corrective gene therapy of inherited skin diseases, 
F I G U R E  2 .  S C H E M A T I C  O V E R V I E W  O F  H U M A N  S K I N  L A Y E R S .  
(adapted from www.wikipedia.org) 
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including vector technology, targeted gene expression, gene replacement, and the 
availability of appropriate animal models for a variety of candidate diseases. In addition, 
an increased understanding of the uptake and trafficking mechanisms inside 
keratinocytes has evolved. The translation into clinical trials and the control of immune 
responses represent challenges for further researches 64.  
5 . 1 0  E P I D E R M A L  S T E M  C E L L S  
The epidermis and its associated structures arise from two stem cell populations within 
the hair follicle and interfollicular regions, one, in the basal layer of skin, giving rise to 
stratified skin layers. A second, the hair follicle stem cell (HFSC), resides in a region of 
the outer root sheath (bulge), and is responsible for the regeneration of hair and 
sebaceous glands. At the start of the hair cycle, stem cells are stimulated to proliferate 
and exit at the base of the bulge. The receding follicle carries the dermal papilla from the 
base of the hair bulb up to the bulge and cyclic alternation in the microenvironment 
stimulates label-retaining cells to exit the niche, divide rapidly and produce a new hair. In 
response to injury, bulge label-retaining cells exit the niche and move upward to repair 
the skin 65;66. Expression profiling of bulge stem cells has identified 97–157 genes that 
are differentially expressed in bulge cells, including fibroblast growth factor 1 and its 
receptor, transforming growth factor activators, Bmp and Wnt pathway inhibitors. ß-
catenin causes de novo follicle morphogenesis and, eventually, skin tumors. Increase in 
ß-catenin levels accelerate the transition from the resting to the growth phase of the hair 
cycle. The transient activation of ß-catenin in adult epidermis may lead to new follicles 
derived from existing follicles, interfollicular epidermis, and sebaceous glands, but not 
from HFSCs within the bulge region. Conditional ablation of Bmpr1a results in hair follicle 
defects. Activation of the Wnt pathway and inhibition of the Bmp pathway appear to be 
necessary for functional ß-catenin/Lef1 transcriptional complexes 17;63. 
5 . 1 1  D E R M A L  S T E M  C E L L S  
The adult hair follicle dermal papilla and dermal sheath cells are developmentally active 
cell populations with a proven role in adult hair follicle-cycling activity and unique 
inductive powers. Cultured papilla and sheath cells lines have extended proliferative 
capabilities and can be directed to lipid and bone differentiation 67. 
The first evidence for the existence of stem cells in the dermis has been provided by 
Toma and colleagues. They have isolated, expanded and characterized a multipotent 
precursor cell from mammalian dermis, termed skin derived precursor (SKP) 5. Recently, 
they have isolated a similar precursor cell from neonatal human foreskin tissue. In the 
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presence of fibroblast growth factor and epidermal growth factor these dermal cells 
proliferate and form spheres in vitro. Addition of transforming growth factor-β during 
culture increased the formation and proliferation of SKP. The human SKP could be 
maintained in culture for long periods of time and still differentiated into neural cells 
(neurons, glia) or mesodermal cells (smooth muscle cells, adipocytes)6. Evidence has 
been provided that human SKP apparently derive from an endogenous multipotent, 
neural crest-related precursor within human foreskin. SKP were described as being 
distinct from MSC and to represent the discovery of a new, multipotent adult stem cell 
17;63. Dermal but not epidermal compartments of the adult hair follicle have some HSC 
activity, suggesting that the capacity to produce hematopoietic cells locally in the skin 
could play a role in wound healing and immune surveillance. Recently, hair follicle 
derived dermal stem cells were isolated, which show a fibroblastic morphology and are 
CD44+CD73+CD90+CD34-. The population has the capacity to differentiate into various 
mesenchymal lineages, such as osteoblasts, adipocytes, chondrocytes, and myocytes 68. 
As a highly accessible source, capable of being discretely isolated, the follicle has 
important potential as a stem cell source for tissue engineering and cell therapy 
purposes. The most obvious therapeutic use of such multipotent adult human precursors 
is cell transplantation. Perhaps equally important is the possibility that expandable adult 
stem cell populations could be used to generate human cell types on an individual basis 
for screening or discovery research and may have implications for certain pathologies in 
which abnormal differentiation occurs in the skin. 
5 . 1 2  C R O S S - T I S S U E - S P E C I F I C  S T E M  C E L L  
C O M P A R I S O N S  
Despite the shortcomings in gene-expression evaluation for many adult stem-cell 
populations, comparison between the molecular signatures of HSC, neural stem cells 
(NSC), bulge stem cells and gastrointestinal stem cells have identified several classes of 
genes that might be expressed in all tissue specific stem cells. For instance, 15–30% of 
genes that are expressed specifically in HSC, but not in hematopoietic progenitor cells, 
are also specifically expressed in NSC-enriched populations; and 14% of genes that are 
expressed in bulge stem cells are also expressed in HSC and neural stem cells. Among 
these are genes involved in Wnt signalling (for example, Tcfs and Fzd7), Notch signalling 
(for example, Hes1), adhesion (for example, Itga6) and transcriptional regulation (for 
example, Bmi1) 1. 
 
31 
 
 
6  O B J E C T I V E  O F  T H E  T H E S I S  
The true potential of stem cells will only be realized through continued effort to increase 
basic scientific understanding at all levels, such as the development of adequate methods 
to achieve a functional phenotype, and attention to safety issues associated with careful 
control of cell localization, proliferation and differentiation. As the phenotype of skin stem 
cells is unknown, the aim of my diploma thesis was to characterize and localize 
mammalian stem cells in murine and human dermis. 
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7  R E S U L T S  &  D I S C U S S I O N  
7 . 1  M U R I N E  S T U D I E S  –  A N A L Y S I S  O F  D O N O R  
C E L L  E N G R A F T M E N T  I N  T I S S U E S  O F  
R E C O N S T I T U T E D  M I C E  
In their recent publication, Meindl et al. from our laboratory have tested dermal cell 
suspensions, cryosections, and whole mounts in newborn and adult mice for HSC marker 
expression 69. Phenotypic analysis revealed that a small population of CD45+ cells and a 
large population of CD45– cells expressed CD34, CD117, and stem cell antigen-1 (Sca-1) 
molecules. When cultivated in selected media supplemented with hematopoietic 
cytokines, total dermal cells, Lin–, and/or highly enriched phenotypically defined cell 
subsets produced hematopoietic and nonhematopoietic colonies. When injected into 
lethally irradiated recipient mice, a small percentage of newborn dermal cells was able to 
migrate into hematopoietic tissues and the skin and survived through the 11-month 
monitoring period. To distinguish between host and donor cells, Meindl et al. have used 
C57BL/6 ROSA26 (CD45.2) mice as donors which express ß-galactosidase (ß-gal) 
systemically. Dermal cells isolated from these mice were injected into congenic mice 
expressing the CD45.1 allele, allowing analysis of donor and host cells for defined 
populations (FACS analysis, ß-gal expression). Briefly, lethally irradiated mice (CD45.1) 
were transplanted with total dermal cells, Lin-, CD34+, CD90+ and CD45+ dermal cells 
from newborn C57BL/6 ROSA26 (CD45.2) mice together with syngeneic (CD45.1) BM 
cells. Recipient mice were sacrificed at selected time points (8-44 weeks), and chimerism 
was evaluated by flow cytometry and ß-gal detection. CD45.2+ donor cells and ß-gal 
activity were observed in hematopoietic tissues (thymus, spleen, lymph nodes, liver and 
BM) and in skin of mice injected with purified CD45+ and Lin- dermal cells. 
ß-gal is encoded by the lacZ gene, which can be detected on DNA and RNA levels by 
polymerase chain reaction technique (PCR) and reverse transcriptase polymerase chain 
reaction (RT-PCR), respectively. In parallel to the phenotypic analysis of recipient mice 
we performed RT-PCRs of hematopoietic tissues and the skin of mice with primers 
specific for the lacZ gene 70 to strengthen the results.  
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In the first series of experiments, skin, thymus, spleen, lymph nodes, liver and BM from 
C57BL/6 ROSA26 and C57BL/6 mice, were tested for lacZ gene expression on genomic 
(F I G .  3 A ) and RNA levels (F I G .  3 B ). Equal amounts of DNAse-treated total RNA were 
used for first-strand cDNA synthesis. The lacZ gene was detected only in ROSA26, but 
not C57BL/6 mice, proving that only ROSA26 mice carry the lacZ gene (positive 
controls). C57BL/6 mice were used as negative controls. 
7 . 1 . 1  L A C Z  W A S  N O T  D E T E C T A B L E  I N  R E C O N S T I T U T E D  M I C E  
To detect lacZ mRNA, and thus the presence of donor cells, in hematopoietic tissues and 
skin of reconstituted CD45.2+ mice (T A B L E  2 ), RT-PCR was performed. To verify 
successful RNA isolation and cDNA synthesis, PCRs with primers specific for the 
expressed housekeeping gene hypoxanthine guanine phosphoribosyltransferase (HPRT) 
were conducted for each sample. Equal amounts of cDNA were used for all PCR reactions. 
As expected, HPRT mRNA was detected in all samples (data not shown), whereas lacZ 
was only detectable in the positive control mice (ROSA26; n=2). We have screened 25 
reconstituted mice for lacZ expression, using primers described by Sibilia et al. 70. 
Surprisingly, in none of the tested organs we detected lacZ gene expression, regardless 
of the source of the injected donor cells (F I G .  4 A ). Consequently, we decided to test lacZ 
primers with different sequences such as those described by Lako et al. 66 (F I G .  4 B ). 
Again, except for the positive controls, we failed to observe lacZ gene expression in any 
of the reconstituted mice (F I G .  4 C ). 
F I G U R E  3 .  D E T E C T I O N  O F  L A C Z  I N  C 5 7 B L / 6  R O S A 2 6  M I C E ,  B U T  N O T  I N  C 5 7 B L / 6  M I C E .  A .  lacZ 
PCR of DNA isolated from skin and hematopoietic tissue of C57BL/6 ROSA26 mice (n = 2) and C57BL/6 mice (n 
= 2), indicating the lack of the lacZ gene in C57BL/6 mice. B .  lacZ RT-PCR of either cDNA or RNA (negative 
controls) isolated from skin and hematopoietic tissues of C57BL/6 ROSA26 mice (n = 2). Forty five cycles were 
performed for lacZ primers. 
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T A B L E  2 .  O V E R V I E W :  I N V E S T I G A T E D  M I C E  A N D  T R A N S P L A N T E D  C E L L  T Y P E S .  
C E L L  T Y P E  
T R A N S P L A N T E D  
C E L L S  
I N J E C T E D / M O U S E  
C E L L  T Y P E  
T R A N S P L A N T E D  
C E L L S  
I N J E C T E D / M O U S E  
adult dermis 1x106 CD90
- 5x104 
CD34- 1x104 CD90
+ 5x104 
CD34+ 1x104 Lin
- 1x106 
CD45+ 1x104 newborn dermis 1x106 
Reconstituted mice were tested for lacZ mRNA levels using 2 different primer pairs. 
Purified populations were isolated from newborn C57BL/6 ROSA 26 mice (see also 
T A B L E  6 . ). 
F I G U R E  4 .  L a c Z  E X P R E S S I O N  A N A L Y S I S  O F  R E C I P I E N T  M I C E  B Y  R T - P C R .  A .  RT-PCR analysis of cDNA 
generated from RNA isolated from skin and hematopoietic tissues of irradiated C57BL/6 mice reconstituted with 
CD34+ cells using primers from Sibilia et al. 70. B .  Comparison of lacZ primer pairs using cDNA from a positive 
control revealed a difference in the size of the lacZ PCR product. C .  RT-PCR analysis of cDNA generated from 
RNA of irradiated C57BL/6 mice reconstituted with dermal cells from adult C56BL/6 ROSA26 mice using Lako 
primers 66. In both experiments (A  & C ) the lacZ gene was only detected in positive controls. Forty five cycles 
were performed for lacZ primers. 
 
36 
 
 
In their reconstitution assays, Meindl et al. 68 injected cells isolated from C57BL/6 
ROSA26 mice carrying the lacZ reporter gene into lethally irradiated C57BL/6 mice. A 
small percentage of the injected cells was able to migrate into hematopoietic tissues and 
the skin and survived through a 11-month monitoring period. CD45.2+ donor cells were 
identified by flow cytometry, and ß-galactosidase activity was detected in cells on 
cytospins. To confirm these data we thought to additionally apply a molecular approach. 
Using the RT-PCR technology we expected to detect the lacZ reporter gene in specific 
organs of the reconstituted mice. Total RNA was isolated from skin, thymus, spleen, 
lymph nodes, liver and BM, transcribed to cDNA and examined for the lacZ mRNA 
expression with two different lacZ primer pairs. The lacZ fragment could not be detected 
in any of the investigated tissues, suggesting that this method may not be sensitive 
enough to detect transplanted cells in the tissues indicated.  
For the establishment of the lacZ-specific RT-PCR method we tested the polymerase, 
primers, PCR-mix and the PCR programme with cDNA obtained from organs of a C57BL/6 
ROSA26 mouse. lacZ was detected in all tissues of this mouse using either of the primer 
pairs. To control the successful RNA isolation and cDNA synthesis we additionally 
performed a PCR, specific for the housekeeping gene HPRT. We could demonstrate the 
presence of HPRT in all samples obtained from either the control mice, or the 
reconstituted mice. Furthermore, to exclude contamination with genomic DNA in our PCR 
procedure we carried out lacZ and HPRT PCRs with the RNA samples and all components 
of the PCR mix separately. As expected, neither lacZ nor HPRT were detected in any of 
the samples.  
We used established lacZ systems acquired from studies by Sibilia et al. 70 and Lako et 
al. 66. The systems differed from each other in the sequences of the primers, as well as in 
the size of the lacZ fragment received from RT-PCR. The results we gained from tests 
with this system were negative. 
Our failure to demonstrate the lacZ reporter gene in the recipient mice can be explained 
by the low frequency of donor cells in the investigated tissues. Another explanation might 
be that we have not analyzed freshly isolated, but frozen tissue. Furthermore, intensive 
inquiries resulted in a sparse list of publications which described the use of the lacZ 
reporter gene system. In comparison to many other reporter genes in mice, the use of 
the lacZ gene seems to be quite unpopular. The application of another reporter gene may 
be more successful. 
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7 . 2  H U M A N  S T U D I E S  –  E X P R E S S I O N  O F  S T E M  
C E L L  M A R K E R S  I N  H U M A N  S K I N  
There are several markers whose expression changes at different rates as primitive 
hematopoietic and non-hematopoietic cells differentiate. By targeting various 
combinations of markers, it has become possible to subdivide this functionally 
heterogeneous mixture of cells into more homogeneous subpopulations. It hast been 
demonstrated that the murine skin contains CD45+ and CD45- populations of cells that 
can be distinguished by the expression of several markers, including stem cell markers, 
some of which might represent candidate stem/progenitor cells 69. Based on these 
observations and the fact that the skin rapidly changes with regard to the cellular 
composition during the first years of life 71, we have decided to investigate skin tissue 
from young donors (6 months up to 4 years after birth), speculating to find precursors 
and stem cells in a higher frequency compared to adults. We performed multi-colour 
immunofluorescence staining of cryostat sections and flow cytometry of total single cell 
suspensions from human foreskin with subsequent analysis using confocal laser scanning 
microscopy (CLSM). Selected cell surface marker combinations were employed to identify 
and localize hematopoietic and non-hematopoietic stem cell candidates. All experiments 
were performed with human foreskin obtained from routine circumcisions.  The use of 
human foreskin has the advantage of easy accessibility, which also makes it ethically 
defensible in comparison to biopsies from other body sites. Moreover, foreskin is hairless 
and, thus, assumed to be devoid of the already well described hair follicle stem cells, 
implying that dermal cells expressing stem cell markers do not represent these cells. 
7 . 2 . 1   C D 3 4  
Cell surface expression of CD34 has become the distinguishing feature used as the basis 
for the enumeration, isolation and manipulation of human HSC. It is downregulated as 
cells differentiate into more mature cells. Confocal microscopy and flow cytometry 
analysis revealed that the dermis contains a high number of cells expressing CD34 (F I G .  
5 A ,  B ). While the majority of CD34+ cells were CD45-, we consistently observed a small 
population of CD34+CD45+ cells (F I G .  5 B ). In repeated experiments we could localize 
CD34+ cells in the papillary and the reticular dermis, arranged in clusters or spread in an 
irregular fashion over the whole dermis, thus, confirming and extending findings by 
Meindl et al. who have shown that a small population of CD45+ cells expressed CD34 in 
murine skin 69. The isolation and cultivation of CD34+CD45+ cells from the human system 
might lead to similar results, and, thus, would represent ideal vehicles for genetic 
 
38 
 
 
manipulation and gene therapy. When cultivated in selected media, these murine 
CD34+CD45+ cells produced hematopoietic and nonhematopoietic colonies. 
 
 
 
 
F I G U R E  5 .  H U M A N  S K I N  H A R B O U R S  C D 3 4 + C D 4 5 +  C E L L S .  A .  Immunofluorescence analysis of cryostat 
sections from human foreskin (2 year-old). Sections were exposed to PE-anti-CD34 and APC-anti-CD45 double 
labeling. Arrow indicates one CD34+CD45+ cell. B .  FACS analysis of human foreskin (3 year-old). Total dermal 
single cell suspension was stained for the indicated markers. Numeric values indicate percentage among living 
cells. Dead cells positive for 7-AAD were excluded and 30.000 events per sample were acquired. 
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Using stem cell markers, such as CD13 and CD90, we identified a subset of 
CD34+CD13+CD90+ cells. CD13 is expressed during hematopoiesis at several different 
stages of myeloid differentiation and on LT-repopulating cells. When expressed on CD34P+P 
cells, it becomes a marker of a progenitor cell population that includes mast cell, 
monocyte and mast cell/monocyte precursors. CD90 is known to stain fibroblasts as well 
as stem cell-enriched cell populations. Triple-staining for CD34+CD13+CD90+ cells on 
whole mounts allowed a clear visualization of blood and lymphatic vessels (CD34+) (F I G .  
6 ).  
F I G U R E  6 .  E X P R E S S I O N  O F  C D 9 0 ,  C D 1 3  A N D  C D 3 4  I N  H U M A N  S K I N .  Immunofluorescence analysis of 
whole mounts (3 year-old). Samples were exposed to PE-anti-CD90, FITC-anti-CD13 and APC-anti-CD34 triple 
labeling.  
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The disadvantage of the whole mount staining compared to cryostat sections is that the 
identification of single cells expressing certain markers is more difficult. In cryostat 
sections we also localized CD34+CD13+CD90+ candidate stem/progenitor (F I G .  7 ). These 
data were confirmed by flow cytometry. We found that approximately 80% of 
CD34+CD90+ cells coexpress CD13 (F I G .  8 ). 
F I G U R E  7 .  H U M A N  S K I N  H A R B O U R S  C D 9 0 + C D 1 3 + C D 3 4 +  C E L L S .  Immunofluorescence analysis of 
cryostat sections from human foreskin (3 year-old). Samples were exposed to PE-anti-CD90, FITC-anti-CD13 
and APC-anti-CD34 triple labeling.  
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F I G U R E  8 .  H U M A N  S K I N  H A R B O U R S  C D 9 0 + C D 3 4 +  C E L L S ,  M O S T  O F  W H I C H  C O E X P R E S S  C D 1 3 .  Total 
dermal cells (human foreskin of a 3-year old child) were stained for the indicated markers and analyzed by flow 
cytometry. Numeric values indicate percentage among mononuclear cells. Dead cells positive for 7-AAD were 
excluded and 10.000 events per sample were acquired. The orange rectangle represents the gate for detection 
of the third antibody analyzed in the histogram. The closed (orange) profile in the histogram illustrates the 
reactivity of CD90+CD34+ cells with an anti-CD13 mAb, the open profile represents an irrelevant, isotype-
matched control mAb. 
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In addition to CD34+CD45+CD13+ cells, we identified CD34-CD45+CD13+, CD34+CD45- 
CD13-, CD34-CD45+CD13- and CD34-CD45-CD13+ cells (F I G .  9  and F I G .  1 0 ). While the 
CD34+CD45+CD13+ cell population indicates undifferentiated cells, CD34-CD45+CD13+ 
cells represent differentiated cells. 
F I G U R E  9 .  E X P R E S S I O N  O F  C D 4 5 ,  C D 1 3  A N D  C D 3 4  I N  H U M A N  S K I N .  Immunofluorescence analysis of 
cryostat sections from human foreskin (4 year-old). Sections were exposed to purified-anti-
CD45+Biotin+Streptavidin-Texas Red, FITC-anti-CD13 and APC-anti-CD34 triple labeling.  
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F I G U R E  1 0 .  E X P R E S S I O N  O F  C D 4 5 ,  C D 1 3  A N D  C D 3 4  I N  H U M A N  S K I N .  Immunofluorescence analysis 
of cryostat sections from human foreskin (3 year-old). Sections were exposed to purified-anti-
CD45+Biotin+Streptavidin-Texas Red, FITC-anti-CD13 and APC-anti-CD34 triple labeling.  
 
44 
 
 
To distinguish between lymphatic and blood vessels, we introduced the Pathologische 
Anatomie Leiden-endothelium (PAL-E) mAb for our investigations. It recognizes a protein 
expressed exclusively by endothelial cells that line blood capillaries and small veins, with 
exception of those in the brain. Tumor blood vessels and the high endothelial venules in 
lymph nodes are particularly PAL-E reactive. In contrast, PAL-E is non-reactive with 
lymphatic capillary endothelial cells and with the arterial endothelium. PAL-E has been 
used extensively to determine if small vessels in the skin and elsewhere are of blood or 
lymphatic origin 72;73. By a combination of CD34, PAL-E and CD90, we could not only 
distinguish between blood (CD34+PAL-E+) and lymphatic vessels (CD34+PAL-E-), but also 
identified CD34+CD90+PAL-E+ cells (F I G .  1 1 ,  white arrows). 
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F I G U R E  1 1 .  E X P R E S S I O N  O F  C D 9 0 ,  C D 3 4  A N D  P A L - E  I N  H U M A N  S K I N .  Immunofluorescence analysis 
of cryostat sections from human foreskin (3 year-old). Sections were exposed to PE-anti-CD90, FITC-anti-CD34 
and APC-anti-PAL-E triple labeling. White arrows indicate CD34+CD90+PAL-E+ cells, red arrows indicate 
CD34+PAL-E+ blood vessels, whereas green arrows indicate CD34+PAL-E- lymphatic vessels. 
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Staining for CD34 and CD14 showed that CD14+ cells are often surrounded by CD34+ 
cells and vessels in the papillary dermis (F I G .  1 2 ).  
Triple staining for CD34, CD14, and CD31 revealed coexpression of CD34 and CD14 on 
certain cells, but not CD31 (F I G .  1 3 ), and coexpression of CD34 and CD31, but not CD14 
(F I G .  1 4 ). CD31 appears on endothelial cells and can be used for measuring 
angiogenesis. In combination with CD34, CD31 is also a marker for myeloid progenitor 
cells. CD31 is normally found on endothelial cells, platelets, macrophages and Kupffer 
cells, granulocytes, T cells, natural killer cells lymphocytes, megakaryocytes, fibroblasts, 
osteoclasts, and neutrophils. Thus, it is conceivable that CD14+CD34+ cells represent 
candidate stem/progenitor cells, as their appearance is quite rare and it has been shown 
that the macrophage/monocyte marker CD14 is also detectable on some CD34+ cells. 
These CD14+CD34+ cells exhibit clonogenicity and multipotency, as shown by their ability 
to differentiate not only into endothelial cells, but also into osteoblasts, adipocytes, or 
neural cells 48. CD34+CD31+ cells might represent endothelial cells or myeloid 
progenitors, though an endothelial character is more likely, due to the relative high 
frequency in the dermis. 
 
 
 
 
F I G U R E  1 2 .  E X P R E S S I O N  O F  
C D 1 4  I N  H U M A N  S K I N .  
Immunofluorescence analysis of 
cryostat sections from human 
foreskin (3 year-old). Sections 
were exposed to FITC-anti-CD34 
and APC-anti-CD14 double 
labelling.  
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F I G U R E  1 3 .  E X P R E S S I O N  O F  C D 1 4 ,  C D 3 1  A N D  C D 3 4  I N  H U M A N  S K I N .  Immunofluorescence analysis 
of cryostat sections from human foreskin (3 year-old). Sections were exposed to purified-anti-
CD14+Biotin+Streptavidin-Texas Red, FITC-anti-CD31 and APC-anti-CD34 triple labeling. Arrow indicates a 
CD14+CD34+CD31- cell. 
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F I G U R E  1 4 .  H U M A N  S K I N  H A R B O U R S  C D 3 1 + C D 3 4 +  C E L L S .  Immunofluorescence analysis of cryostat 
sections from human foreskin (3 year-old). Sections were exposed to purified-anti-CD14+Biotin+Streptavidin-
Texas Red, FITC-anti-CD31 and APC-anti-CD34 triple labeling.  
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7 . 2 . 2  C D 1 1 7  
CD34 is the most common marker for the selection of HSC. In peripheral blood, 60–80% 
of CD34+ cells coexpress CD117, another marker for stem cell separation. The expression 
level of CD117 on CD34+P cells is usually high enough to allow its use in hematopoietic 
cell isolation methods. Furthermore, CD117 is an important cell surface marker for the 
identification of certain types of hematopoietic progenitors in the BM. Some of the BM 
stem cells that express CD117 but not CD34, generate angiogenic cytokines and 
differentiate into endothelial cells 74. Additionally, mast cells, epidermal melanocytes, and 
interstitial cells of Cajal in the digestive tract express CD117. Using confocal microscopy 
analysis, we could identify CD117+ cells localized both in the papillary and the reticular 
dermis (F I G .  1 5 ).  
For their further characterization we included CD45 in our staining protocol. Occasionally, 
we found CD117+PCD45+P cells which most likely represent mast cell progenitors (F I G .  
1 6 A ). The majority of CD117+ cells surprisingly failed to express CD45 (F I G .  1 6 B ). As the 
presence of so high numbers of melanocytes in the dermis appears unlikely 75, it is 
possible that the levels of CD45 are below those detectable by immunofluorescence. 
 
 
F I G U R E  1 5 .  E X P R E S S I O N  O F  
C D 1 1 7  I N  H U M A N  S K I N .  
Immunofluorescence analysis of 
cryostat sections from human 
foreskin (3 year-old). Sections 
were exposed to PE-anti-CD117 
and Sytox Green (nucleic acid 
staining). 
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7 . 2 . 3  C D 1 3 3  
CD133 was originally described as a marker for human HSC and has recently been 
proposed as a universal marker for tissue stem/progenitor cells 57. Its expression pattern 
overlaps with, but is not identical to that of CD34. CD133 is expressed on a majority of, 
but not all, CD34P+P cells. These include immature progenitors, monocyte/granulocyte 
progenitors and some erythroid progenitors. It also appears to be expressed on CD34P- P 
HSC identified in human cord blood 58. In our studies, we identified a few CD133+ cells in 
the human papillary dermis (F I G .  1 7 ).  
F I G U R E  1 6 .  E X P R E S S I O N  O F  C D 1 1 7  A N D  C D 4 5  I N  H U M A N  S K I N .  Immunofluorescence analysis of 
cryostat sections from human foreskin (3 year-old). Sections were exposed to PE-anti-CD117 and APC-anti-
CD45 double labeling. 
F I G U R E  1 7 .  E X P R E S S I O N  O F  
C D 1 3 3  I N  H U M A N  S K I N .   
Immunofluorescence analysis of 
sections from human foreskin (3 
year-old). Cryostat sections were 
exposed to purified-anti-
CD133+Biotin+Streptavidin 
Texas Red and Sytox Green 
(nucleic acid staining). 
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Double labeling of CD133 and CD34 revealed some CD133+CD34+ cells in the human 
dermis (F I G .  1 8 ).  
We also encountered CD133+CD45+CD34- cells (F I G .  1 9 ). This finding is in concordance 
with a previous observation showing that CD133+CD34- HSC are present in cord blood 
and imply that dermal CD133+CD45+CD34- cells may represent candidate HSC. 
 
F I G U R E  1 8 .  H U M A N  S K I N  H A R B O U R S  C D 1 3 3 + C D 3 4 +  C E L L S .  Immunofluorescence analysis of cryostat 
sections from human foreskin (1 year-old). Sections were exposed to purified-anti-CD133+Biotin+Streptavidin 
Texas Red, FITC-anti-CD34 and Dapi (nucleic acid staining). 
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F I G U R E  1 9 .  H U M A N  S K I N  H A R B O U R S  C D 1 3 3 + C D 4 5 + C D 3 4 - C E L L S .  Immunofluorescence analysis of 
cryostat sections from human foreskin (3 year-old). Sections were exposed to purified-anti-
CD133+Biotin+Streptavidin Texas Red, FITC-anti-CD34 and APC-anti-CD45 triple labelling. Arrows indicate a 
CD133+CD45+CD34- cell. 
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7 . 2 . 4  C D 1 5 0  
Purification of HSC has always been a problem, because no definitive marker was known. 
Recently, purification of murine HSC has improved due to the introduction of the SLAM 
family receptors. CD150, CD244, and CD48 are differentially expressed among 
hematopoietic progenitors in a way that correlates with progenitor primitiveness. In mice 
CD150 is expressed on long-term repopulating cells. It has most recently been shown, 
that CD150 family molecules are also present on human HSC 76. As CD150 expression 
has never been tested on human skin cells, we included this receptor in our search for 
stem cells in the human dermis. Indeed, we could identify CD150+CD34+ (F I G .  2 0 A ) and 
CD150+CD45- cells (F I G .  2 0 B ). Moreover, a few cells express CD150, CD34 and CD45, 
implying a stem cell character (F I G .  2 1 , arrow). 
F I G U R E  2 0 .  F E W  D E R M A L  C E L L S  E X P R E S S  C D 1 5 0 .  Immunofluorescence analysis of cryostat sections from 
human foreskin (3 year-old). Sections were exposed to purified-anti-CD150+Biotin+Streptavidin Texas Red and 
FITC-anti-CD34 double labeling (A ) or purified-anti-CD150+Biotin+Streptavidin Texas Red and FITC-anti-CD45 
double labeling (B ). 
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F I G U R E  2 1 .  H U M A N  S K I N  H A R B O U R S  C D 1 5 0 + C D 3 4 + C D 4 5 +  C E L L S .  Immunofluorescence analysis of 
cryostat sections from human foreskin (3 year-old). Sections were exposed to purified-anti-
CD150+Biotin+Streptavidin Texas Red, FITC-anti-CD34 and APC-anti-CD45 triple labeling. Arrow indicates a 
CD150+CD34+CD45+ cell. 
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7 . 2 . 5  C D 3 1 8
CD318 is expressed on HSC, epithelial cells, and on cells with a phenotype reminiscent of 
MSC. The expression of CD318 on normal human hematopoietic cells is restricted to a 
subset of CD34+ cells. Similar to CD34 and CD133, CD318 may thus be useful for the 
enrichment of human HSC and progenitor cells, but not for their discrimination. 
We performed staining for CD318+ cells in human skin, and by employing various 
markers we could identify certain CD318+ cell subsets. In first attempts we localized 
solitary CD318+ cells spread over the dermis in low counts, preferentially located in the 
papillary dermis. Furthermore, we found that all that all keratinocytes expressed CD318 
(F I G .  2 2 A ), what is consistent with a most recent finding 77. Approximately 9% of total 
dermal cells expressed CD318 and, as determined by flow cytometry, 0.39% of total 
dermal cells coexpress CD318 and CD34 (F I G .  2 2 B ). 
According to our immunofluorescence staining data, it appeared quite unlikely that all 
CD318+ single positive cells are from the dermis. Reasoning that keratinocytes might 
have contaminated our dermal cell preparations, we used the K14 mAb, an antigen that 
is expressed in basal keratinocytes, to better define the CD318+ population. Indeed, we 
F I G U R E  2 2 .  H U M A N  S K I N  H A R B O U R S  D I F F E R E N T  C D 3 1 8 +  S U B S E T S .  A . Immunofluorescence analysis of 
cryostat sections from human foreskin (3 year-old). Sections were exposed to purified-anti-
CD318+Biotin+Streptavidin Texas Red and Sytox Green (Nucleic acid staining). B ,  C .  FACS analysis of human 
foreskin (3 year-old). Total dermal single cell suspension was stained for the indicated markers. D .  
Immunofluorescence analysis of cryostat sections from human foreskin (1 year-old). Sections were exposed to 
AF647-anti-CD318 and FITC-anti-K14 double labeling. 
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found that all K14+ keratinocytes coexpressed CD318, showing that epithelial cells 
contaminate our dermal cell suspensions (F I G .  2 2 C , D ). Thus, CD318 is also an excellent 
surface marker for keratinocytes and clearly visualizes all epidermal layers (F I G .  2 3 ). 
  
F I G U R E  2 3 .  C D 3 1 8  C L E A R L Y  V I S U A L I Z E S  T H E  T O T A L  E P I D E R M I S .  Immunofluorescence analysis of 
cryostat sections from human foreskin (1 year-old). Sections were exposed to AF555-anti-CD45, FITC-anti-K14 
and AF647-anti-CD318 triple labeling.  
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To test whether CD318+CD34+ cells may represent HSC candidates, we included a CD45 
mAb in our staining protocol. Indeed, we identified few CD318+CD45+CD34- (F I G .  2 4 , 
arrows) and CD318+CD45+CD34+ cells (F I G .  2 5 ). 
F I G U R E  2 4 .  H U M A N  S K I N  H A R B O U R S  C D 3 1 8 + C D 4 5 + C D 3 4 -  C E L L S .  Immunofluorescence analysis of 
cryostat sections from human foreskin (3 year-old). Sections were exposed to purified-anti-
C318+Biotin+Streptavidin-Texas Red, FITC-anti-CD34 and APC-anti-CD45 triple labeling. Arrows indicate 
CD318+CD45+CD34- cells. 
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F I G U R E  2 5 .  H U M A N  S K I N  H A R B O U R S  C D 3 1 8 + C D 4 5 + C D 4 5 +  C E L L S .  Immunofluorescence analysis of 
cryostat sections from human foreskin (3 year-old). Sections were exposed to purified-anti-
CD318+Biotin+Streptavidin-Texas Red, FITC-anti-CD34 and APC-anti-CD45 triple labeling.  
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So far our results imply that some CD318+ dermal cells are closely linked to CD34+ cells. 
To better characterize their nature (i.e. endothelial progenitors) we combined mAb for 
CD34 and CD31, and, furthermore, PAL-E, to distinguish between lymphatic and blood 
vessels. Immunofluorescence analysis showed that the CD34+CD318- cells are part of 
blood vessels, as they expressed CD31 and PAL-E (F I G S .  2 6 ,  2 7 ,  2 8 ,  and 2 9 ). We also 
found CD31+PAL-E- lymphatic vessels (F I G .  3 0 ). Occasionally CD318+CD31+PAL-E+ cells, 
were found.  
 
  
F I G U R E  2 6 .  C D 3 1 8 +  C E L L S  D O  N O T  C O E X P R E S S  C D 3 1  A N D  C D 3 4  I N  H U M A N  S K I N .  
Immunofluorescence analysis of cryostat sections from human foreskin (3 year-old). Sections were exposed to 
purified-anti-CD318+Biotin+Streptavidin-Texas Red, FITC-anti-CD31 and APC-anti-CD34 triple labeling.  
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F I G U R E  2 7 .   C D 3 1 8 +  C E L L S  D O  N O T  C O L O C A L I Z E  W I T H  C D 3 1 + P A L - E +  H U M A N  D E R M A L  C E L L S .  
Immunofluorescence analysis of cryostat sections from human foreskin (3 year-old). Sections were exposed to 
purified-anti-CD318+Biotin+Streptavidin-Texas Red, FITC-anti-CD31 and APC-anti-PAL-E triple labeling.  
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F I G U R E  2 8 .  M O S T  O F  T H E  C D 3 1 8 +  C E L L S  D O  N O T  E X P R E S S  C D 3 4  A N D  P A L - E .  Immunofluorescence 
analysis of cryostat sections from human foreskin (3 year-old). Sections were exposed to purified-anti-
CD318+Biotin+Streptavidin-Texas Red, FITC-anti-CD34 and APC-anti-PAL-E triple labeling.  
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F I G U R E  2 9 .  A  F E W  C D 3 1 8 +  C E L L S  C O E X P R E S S  C D 3 4  A N D  P A L - E .  Immunofluorescence analysis of 
cryostat sections from human foreskin (1 year-old). Sections were exposed to PE-anti-PAL-E, FITC-anti-CD34, 
AF647-anti-CD318 triple labeling.  
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F I G U R E  3 0 .  A  F E W  C D 3 1 8 +  C E L L S  C O E X P R E S S  C D 3 4  A N D  P A L - E .  Immunofluorescence analysis of 
cryostat sections from human foreskin (3 year-old). Sections were exposed to purified-anti-
CD318+Biotin+Streptavidin-Texas Red, FITC-anti-CD31 and APC-anti-PAL-E triple labeling.  
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Further analysis of CD318+CD34+ cells revealed coexpression of CD13. As CD13+ cells 
have been shown to have LT-repopulating capacity, CD318+ cells may also have this 
ability 59 (F I G .  3 1  and F I G .  3 2 ). In conclusion, similar to CD34 and CD133, CD318 may 
be useful for the enrichment of human HSC and progenitor cells, but not for their 
discrimination. 
 
F I G U R E  3 1 .  H U M A N  S K I N  H A R B O U R S  C D 3 1 8 + C D 1 3 + C D 3 4 +  C E L L S .  Immunofluorescence analysis of 
cryostat sections from human foreskin (3 year-old). Sections were exposed to purified-anti-
CD318+Biotin+Streptavidin-Texas Red, FITC-anti-CD13 and APC-anti-CD34 triple labeling.  
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F I G U R E  3 2 .  H U M A N  S K I N  H A R B O U R S  C D 3 1 8 + C D 1 3 + C D 3 4 +  C E L L S .  Immunofluorescence analysis of 
cryostat sections from human foreskin (3 year-old). Cryostat sections were exposed to purified-anti-
CD318+Biotin+Streptavidin-Texas Red, FITC-anti-CD13 and APC-anti-CD34 triple labeling.  
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A frequently used marker for myofibroblasts and vascular smooth muscle cells is α-
smooth muscle actin (α-SMA) 78. Immunohistochemical and immunoelectron microscopy 
studies revealed the presence of α-SMA in fibroblasts located in the connective tissue 
sheath of human anagen hair follicles. α-SMA was detected only in fibroblasts located in 
the innermost layer of the transverse collagenous fibres. Since α-SMA is located in cells 
with contractile potential, this newly identified layer may play an important role in the 
morphological changes of the lower portion of the hair follicle during the hair growth 
cycle 79. The combination of the markers CD318, CD34 and α-SMA revealed that distinct 
cells in the dermis coexpress these proteins (F I G .  3 3 ). Interestingly, α-SMA+ cells appear 
quite regularly, even though only few hair follicles are present in foreskin. Human fetal 
cord blood contains a population of cells that may differentiate toward both an 
endothelial and a smooth muscle phenotype in culture. For the identification of these 
cells, the expression of α-SMA was used. Following culture in an endothelial cell-
promoting environment, CD34+ isolates produced endothelial-like cells that expressed 
alpha-SMA 80. Thus, it is conceivable that CD318+α-SMA+CD34+ population may also 
have the potential to form both hematological and endothelial cells (F I G .  3 4 ). 
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F I G U R E  3 3 .  H U M A N  S K I N  H A R B O U R S  C D 3 1 8 + α - S M A + C D 3 4 +  C E L L S .  Immunofluorescence analysis of 
cryostat sections from human foreskin (3 year-old). Sections were exposed to purified-anti-
CD318/Biotin/Streptavidin-Texas Red/FITC-anti-α-SMA/APC-anti-CD34 triple labeling.  
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F I G U R E  3 4 .  H U M A N  S K I N  H A R B O U R S  C D 3 1 8 + α - S M A + C D 3 4 +  C E L L S .  Immunofluorescence analysis of 
cryostat sections from human foreskin (3 year-old). Sections were exposed to purified-anti-
CD318/Biotin/Streptavidin-Texas Red/FITC-anti-α-SMA/APC-anti-CD34 triple labeling.  
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8   M A T E R I A L S  &  M E T H O D S  
8 . 1  A P P A R A T U S E S  A N D  I N S T R U M E N T S  
CO2 incubator (Heraeus, Vienna, Austria)  
Confocal laser scanning microscope (CLSM 510, Zeiss, Jena, Germany) 
Cooling centrifuges (Heraeus) 
Centrifuge 5415 R (Eppendorf, Hamburg, Germany) 
Electrophoresis chamber (Sub Cell GT, Bio-Rad Laboratories, Hercules, CA, USA) 
Fluorescence-activated cell sorter (FACSCalibur; Becton Dickinson, San Jose, CA, USA) 
Forceps 
Freezers (-20°C, -80°C) 
Fridges 
ImmEdge pen (Vector Laboratories, Inc., Burlingame, CA, USA) 
JungCM1800 Cryostat (Leica Microsystems, Wetzlar, Germany) 
Laminar flow (Holten, Allerod, Denmark) 
LSM Image Browser (Zeiss) 
LumiAnalyst-software (Roche, Penzberg, Germany) 
Microcentrifuges (Eppendorf) 
Pipetaid (Costar, Cambridge, MA, USA) 
Pipetmen (2 μl, 20 μl, 200 μl, 1 ml; Gilson, Middleton, WI, USA) 
Power supply (Power Pac 300 power supply, Bio-Rad Laboratories) 
PTC 200 – Peltier Thermal Cycler (MJ Research Inc., Waltham, MA, USA) 
Scale (Sartorius, Vienna, Austria) 
Scalpels 
Scissors 
Stainless steel metal mesh  
Transilluminator (Lumi-Imager, Boehringer-Mannheim, Mannheim, Germany) 
U-2000 spectrophotometer (Hitachi, San Jose, CA, USA) 
Vortex Genie 2 (Lactan, Graz, Austria) 
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8 . 2  P L A S T I C  M A T E R I A L  
Cell strainer (70 μm; Falcon, Lincoln Park, New Jersey, USA) 
Culture dishes (35 mm; Stem Cell Technologies, Vancouver, Canada) 
Eppendorf tubes (1.5 ml, 2 ml; Eppendorf) 
Gloves 
Microscope glass cover slips (24x50 mm; Chance proper LTD, Warley, UK) 
Microscope slides (ChemMate Capillary Gap Microscope Slides, DakoCytomation, 
Glostrup, Denmark) 
Microtubes for flow cytometry (Micronic, Lelystad, The Netherlands) 
PCR reaction tubes (Eppendorf) 
Petri dishes for tissue culture (100 x 20 mm; Corning, NY, USA)  
Pipettes (5 ml, 10 ml, 25 ml and 50 ml; Corning) 
Polypropylene tubes (15 and 50 ml; Falcon) 
Sterile tips (1-100 and 200-1000 μl; Corning) 
Swabs  
Tissue culture plates (Nunc, Roskilde, Denmark) 
8 . 3  R E A G E N T S  
1 kb DNA ladder (Invitrogen, Carlsbad, CA, USA) 
2-propanol (Merck, Dortmund, Germany) 
7-amino-actinomycin D (Sigma, Saint Louis, MO, USA) 
Acetone (p.a.; Merck) 
Agarose 
Ammonium chloride solution (0.8% NH4Cl/0.1 mM EDTA; Stem Cell Technologies) 
Ammoniumthiocyanate (3.8% in PBS) 
Antibodies (see T A B L E  5 . ) 
Betaisodona (10%, Mundipharma, Vienna, Austria) 
Bovine serum albumin (BSA, Sigma) 
Chloroform 
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DEPC-treated water 
Desoxyribonuclease I (DNase I, from bovine pancreas, Sigma) 
Dimethylsulfoxide (DMSO) 
Dispase II (neutral protease, grade II, Roche, Basel, Switzerland) 
DNAse buffer 
dNTP mix (Invitrogen, Carlsbad, CA, USA) 
Ethanol (Merck) 
Ethidium bromide 
Ethylenediaminetetraacetic acid (EDTA, Merck) 
FACS buffer (PBS supplemented with 2% FCS, 0.01% NaN3 and 0.5 mM EDTA)  
Fluorescent mounting medium (Dako, Vienna, Austria) 
Isoamylalcohol 
Liberase Blendzyme 3 (10.7 Wünsch units in 20 ml PBS; Roche) 
Methanol (Merck) 
OCT compound (Tissue Tek, Zoeterwoude, The Netherlands) 
Phenol 
Phosphate-buffered saline (PBS 1x, Gibco Life Technologies, Carlsbad, CA, USA) 
Second-step and third-step reagents (see T A B L E  5 . ) 
SuperScript II RT kit (Invitrogen) 
Taq polymerase II (Roche) 
TRIS-acetate/EDTA (TAE) 
TRIzol reagent (Invitrogen) 
8 . 4  M E D I A ,  S E R A  A N D  S U P P L E M E N T S  
Fetal calf serum (FCS, PAA Laboratories, Linz, Austria) 
Goat serum (Sera-Lab Ltd., Sussex, England) 
Mouse serum (self made) 
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8 . 5  E X P E R I M E N T A L  A N I M A L S  
C57BL/6 (CD45.1; Charles River Wiga GmbH, Sulzfeld, Germany and Centre de 
Developèment des Techniques Avanceés pour l´expérimentation animale, Orléans, 
France), and C57BL/6 ROSA-26 (CD45.2) 81 (The Jackson Laboratory, Bar Harbor, Maine) 
mice were bred and maintained at the local animal facility. Newborn mice were obtained 
from timed pregnancies, taking the appearance of a vaginal plug as day 0 of gestation. 
All mouse procedures were performed with consent from the Institutional Committee of 
Animal Experimentation of the Medical University of Vienna and by the Austrian Ministry 
of Science and Education (GZ 66.009/177-Pr/4/2002, GZ 66.009/81-BrGT/2004). 
To distinguish between host and donor cells, C57BL/6 ROSA-26 (CD45.2) mice were used 
as donors that express ß-galactosidase systemically. Consequently, these donor cells can 
be tested for ß-gal expression by their “blue” appearance. Donor cells were injected into 
congenic mice expressing the CD45.1 allele, thus, allowing analysis of donor and host 
cells for defined populations. Briefly, adult (8- to 12-week old) female C57BL/6 (CD45.1) 
mice were given sterile, acidified water (pH 3.0) ad libitum for 2 weeks. Subsequently, 
mice were exposed to 7.5 Gray total body γ-irradiation in a split dose with a 3 h interval. 
Five hours after irradiation, inocula containing total dermal cells (1x107/mouse), Lin- 
dermal cells (1x107/mouse), CD34-, CD34+, CD90-, CD90+ or CD45+ dermal cells (1x103-
1x104/mouse) from C57BL/6 ROSA-26 newborn mice (T A B L E  5 ) or for control purposes, 
BM cells (1x107/mouse) from C57BL/6 ROSA-26 adult mice were injected intravenously 
into the tail vein or intraperitoneally using a syringe fitted with a 25-gauge needle, in the 
presence or absence of syngeneic BM (1:10). Control mice received 50 µl PBS. At least 3 
mice per group were used for each experimental condition. Total dermal cells from adult 
mice but less so from newborn mice often failed to reconstitute intravenously 
transplanted recipient mice because of cellular aggregation causing fatal embolic 
formation. To determine donor chimerism, tail-vein blood samples were first analyzed 6 
weeks after transplantation and then every second month. Additionally, recipient mice 
were sacrificed at selected time points (8-44 weeks), and cells from BM, spleen, liver, 
lymph nodes, thymus, epidermis and dermis were double-stained with anti-CD45.2 and a 
panel of mAb against Lin markers to detect donor-derived-cells to monitor engraftment 
(F I G .  3 5 ). 
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F I G U R E  3 5 .  E X P E R I M E N T A L  D E S I G N .  
(modified with permission from Meindl et al. 69) 
Chimerism analysis 
FACS analysis 
ß-gal staining 
RT-PCR ? 
dermal cells 
CD45.2 
8-44 weeks 
CD45.1 
BM, spleen, liver, 
lymph nodes, thymus, 
skin 
8 . 6  T O T A L  D N A  I S O L A T I O N  
Mouse tissue (stored at -20°C) was incubated in 500 μl tail buffer (50 mM Tris-HCl pH 8, 
100 mM EDTA, 100 mM NaCl, 1% SDS) plus 25 μl Proteinase K shaking O/N (overnight) 
at 55°C. After mixing for 5 min, 170 μl of saturated NaCl (6 M) were added, and mixed 
again. Samples were centrifuged at 16.1 rcf (relative centrifugal force) for 10 min, 
supernatants (without top phase and pellet) were transferred to new tubes. Five hundred 
μl of isopropanol were added, the sample mixed for 2 min, and spinned at 16.1 rcf for 5 
min. The remaining pellet was washed with 1.5 ml of 70% EtOH and spinned at 16.1 rcf 
for 5 min. Washed pellet was resuspended in 300–400 μl TE buffer (10 mM Tris-HCl pH 
8, 1 mM EDTA), according to the size of pellets. Samples were incubated, gently shaking, 
for two hours at 37°C, and stored at 4°C until use. 
8 . 7  T O T A L  R N A  I S O L A T I O N  
Mouse tissue (stored at -20°C) was homogenized in 1-1.5 ml Trizol and then incubated 
for 5 min at room temperature (RT). Per 1 ml Trizol 200 μl trichlormethane/chloroform 
were added and mixed for 10 sec. After 10 min of centrifugation at 16.1 rcf, the aqueous 
phase was transferred into a fresh tube and mixed with 500 μl of isopropanol. Samples 
were incubated (10 min, RT) and then centrifuged at 16.1 rcf for 10 min. The RNA pellet 
was washed with 1 ml 70% ethanol, mixed and centrifuged (5 min, 4°C). The pellet was 
air-dried, resuspended in DEPC-H2O and incubated (5 min, 65°C). Samples were stored 
shock-frozen at -20°C until use. 
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8 . 8  D N A S E  T R E A T M E N T  
RNA samples were mixed with 5 μl 10x DNAse buffer, 2 μl DNAse I, 1 μl RNAse inhibitor 
and with DEPC-H2O up to a total volume of 50 μl. The mix was incubated (25 min, RT) 
and subsequently 50 μl DEPC-H2O and 50 μl of cholorform/isoamylalcohol/phenol 
(24:1:25) were added. The RNA solution was centrifuged at 16.1 rcf for 5 min. The 
aqueous phase was transferred and mixed with 2.5x volume EtOH and 1/10 volume 3M 
sodiumacetate. After 5 min centrifugation at 4°C, the RNA pellet was washed with 0.5 ml 
70% EtOH and again centrifuged. The pellet was resuspended in 20 μl DEPC-H2O. The 
concentration of isolated total RNA of each sample was quantified by measuring the 
optical density at 260 nm with a spectrophotometer at a dilution of 1:100. Samples were 
stored shock-frozen at -20°C until use. 
8 . 9  C D N A  S Y N T H E S I S  
For the reverse transcriptase reaction an amount of 2 μg of total RNA, 1 μl dNTP mix, 3 
μl of random hexamers and DEPC-H2O were mixed to a total volume of 10 μl. The 
samples were incubated (5 min, 65°C) and then put on ice for 1 min. Nine μl of the 
reaction mix (2 μl 10x RNA buffer, 4 μl 25 mM MgCl2, 2 μl  0.1 M DDT, 1 μl  RNAse OUT) 
were pipetted into the RNA samples and incubated (2 min, RT). One μl of SuperScript II 
RT was added to the reaction mix, except for the RT- control, and incubated (10 min, 
25°C), and subsequently for 50 min at 42°C. The reaction was terminated at 70°C (15 
min). To remove the RNA 1 μl of RNAse H was added and incubated (20 min, 37°C). The 
cDNA samples were diluted 1:1 with DEPC-H2O. 
8 . 1 0  P O L Y M E R A S E  C H A I N  R E A C T I O N  ( P C R )  
8 . 1 0 . 1  P R E P A R A T I O N  O F  T H E  P C R  M A S T E R  M I X  
Twenty three μl of the PCR master mix consisted of 5.5 μl dH2O, 2.5 μl 10x GB (670 mM 
Tris-HCl pH8, 166 mM (NH4)2SO4, 67 mM MgCl2, 50 mM ß-mercaptoethanol, 67 μM 
EDTA), 2.3 μl DMSO, 2.5 μl 10x DNTPs, 5 μl primer 1, 5 μl primer 2, 0.2 μl aTaq 
polymerase. 
8 . 1 0 . 2  R E A C T I O N  S E T - U P  
Equivalents of the above master mix were pipetted into 0.5 ml PCR tubes prior to the 
addition of template cDNA (2 μl per reaction). 
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8 . 1 0 . 3  T H E R M A L  P R O T O C O L  
The PCR amplification profile employed 45 cycles of denaturation (1 min, 94°C), primer 
annealing (1 min, 58°C) and primer extension (1 min 30 sec, 65°C) with a final 
extension step (10 min, 65°C). The PCR products were analyzed immediately or stored 
O/N at 4°C. 
8 . 1 0 . 4  S E Q U E N C E S  O F  P R I M E R S  F O R  D E T E R M I N A T I O N  O F  m R N A  
E X P R E S S I O N  
Primers for RT-PCR were purchased from VBC-Genomics, Vienna, Austria (T A B L E  3 . ). 
T A B L E  3 .  P R I M E R  S E Q U E N C E S .    
T A R G E T   P R I M E R  P A I R S  
lacZc 5 – CGC CAG CTG GCG TAA TAG CG – 3 5 – CTG TCC TGG CCG TAA CCG AC – 3 
lacZd 5 – CGC TCA CAT TTA ATG TTG ATG AAA GC – 3 5 – TCC AGA TAA CGT CCG TCA CTC CAA – 3 
HPRTe 5 – TTG CTC GAG ATG TGA TGA AGG A – 3 5 – AAA GTT GAG AGA TCA TCT CCA CCA A – 3 
8 . 1 0 . 5  A G A R O S E  G E L  E L E C T R O P H O R E S I S  
PCR products were analyzed by electrophoresis on a 1% agarose gel in 1x TAE buffer (40 
mM Tris, 20 mM acetic acid, 1 mM EDTA). Agarose was melted for 60 sec, shaken and 
heated for additional 60 sec. After cooling, 1% of ethidium bromide was added, the gel 
was poured into a gel tray, and allowed to set for 20 min. The comb was removed, the 
gel placed into an electrophoresis chamber and filled with 1% TAE. Five μl of gel loading 
dye was added to 25 μl of PCR product and loaded onto the gel. To determine the length 
of PCR products a 1 kb ladder was included on the gel. Gels were run at 95 V to 135 V 
depending on the size of the gel and visualized with an UV transilluminator and analyzed 
with the LumiAnalyst-software. 
8 . 1 1  P R E P A R A T I O N  O F  H U M A N  S K I N  
Skin was obtained from routine circumcisions of volunteers after informed consent (EK 
Nr. 555/2005). Foreskin was disinfected (betasiodona/PBS, 10 min) and rinsed with 70% 
ethanol before further use. Skin was spread, epidermal side down, on a petri dish, and 
muscle and adipose tissue was scraped away with a scalpel blade. 
 
 
                                                 
c Complete coding regions for gene of interest were obtained from Sibilia et al. 70.  
d Complete coding regions for genes of interest were obtained from Lako et al. 66. 
e Complete coding regions for gene of interest were obtained from Sibilia et al. 70.  
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8 . 1 2  P R E P A R A T I O N  A N D  F L U O R E S C E N C E  
S T A I N I N G  O F  D E R M A L  S H E E T S  
Foreskin was cut into small pieces (3 x 3 mm) and placed dermal side down on 3.8% 
ammoniumthiocyanate (25 min, 37°C). After separating epidermis and dermis, tissues 
were washed with PBS. Dermal sheets were cut into even smaller pieces and fixed in 2% 
PFA (30 min, RT). For fluorescence staining dermal sheets were incubated with primary 
Ab (O/N, 4°C, or 1 h, 37°C). When the mAb was purified, second- and third-step 
reagents were applied (1 h, RT), and blocked with an adequate serum (5% serum in 
PBS). After washing in PBS, sheets were incubated with secondary and tertiary Ab (O/N, 
4°C, or 1 h, 37°C). Specificity of staining was confirmed using isotype-matched control 
mAb. Dermal sheets were mounted and analyzed with CLSM. 
8 . 1 3  P R E P A R A T I O N  A N D  F L U O R E S C E N C E  
S T A I N I N G  O F  C R Y O S E C T I O N S  
Foreskin was cut into small stripes (10 x 3 mm), rolled in and shock-frozen in OCT. Five 
μm sections were mounted on capillary gap microscope slides, fixed in acetone (10 min, 
ice-cold) and stored at -20°C or stained immediately.  
Sections were encircled with an ImmEdge pen and washed in PBS. If necessary, sections 
were blocked with adequate sera. Primary Ab was incubated (O/N, 4°C, or 1h, 37°C). If 
Ab was purified, second- and third-step reagents were applied (1 h, RT), and blocked 
with adequate serum (5% serum in PBS). After washing in PBS, skin sections were 
incubated with secondary and tertiary Ab (O/N, 4°C, or 1 h, 37°C). Specificity of staining 
was confirmed using isotype-matched control mAb. Nucleic acid staining was performed 
with either Dapi or Cytox reagents. Slides were mounted with fluorescent mounting 
medium, analyzed with a CLSM and stored at 4°C. 
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8 . 1 4  C O N F O C A L  L A S E R  S C A N N I N G  M I C R O S C O P Y   
To identify and reveal co-localization of certain proteins of interest on dermal/epidermal 
cells, CLSM was performed. The advantage of confocal microscopy is the ability to collect 
light from a single plane. This is accomplished by imaging objects through a small pinhole 
aperture, thereby preventing detection of all light except for that originating from a thin 
optical section. Fluorescence recordings were performed by means of a confocal laser 
scanning setup, equipped with an argon laser, exciting at 458, 477, 488 and 514 nm, a 
helium/neon laser, single excitation 543 nm, and a second helium/neon laser, excitation 
633 nm (T A B L E  4 . ). 
 
T A B L E  4 .  P E A K  E X C I T A T I O N  A N D  E M I S S I O N  W A V E L E N G T H S  O F  
F L U O R O C H R O M E S  U S E D  F O R  C L S M .  
F L U O R O C H R O M E  E X C I T A T I O N  E M I S S I O N  E X C I T A T I O N  L A S E R  
Alexa Fluor 546 556 nm 573 nm HeNe 1 (458 nm) 
Alexa Fluor 555 555 nm 565 nm HeNe 1 (458 nm) 
Alexa Fluor 647 650 nm 668 nm HeNe 2 (633 nm) 
APC 650 nm 660 nm HeNe 2 (633 nm) 
FITC 495 nm 520 nm Ar (488 nm) 
PE 470 nm 576 nm HeNe 1 (543 nm) 
Lasers required for excitation of individual fluorochromes are indicated. 
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∗ A M E R S H A M , Piscataway, NJ, USA; B I O L E G E N D , San Diego, CA, USA; B D  B I O S C I E N C E S , San Jose, CA, 
USA; H A N S - J Ö R G  B Ü H R I N G , Department of Internal Medicine, University of Tübingen, GER; C A L T A G , 
Burlingame, CA, USA; F I T Z G E R A L D , Concord, MA, USA; I M M U N O T E C H , Marseille, F; I N V I T R O G E N , Carlsbad, 
CA, USA; O T T O  M A J D I C , Institute of Immunology, Medical University of Vienna, AUT; M E D A C , Hamburg, GER; 
M I L T E N Y I , Bergisch Gladbach, GER; M O L E C U L A R  P R O B E S , Eugene, OR, USA; S E R O T E C , Oxford, UK; 
S I G M A , Saint Louis, MO, USA; V E C T A S H I E L D , Burlingame, CA, USA. 
 T A B L E  5 .  A N T I B O D I E S ,  S E C O N D - S T E P  A N D  T H I R D - S T E P  R E A G E N T S .  
A B  S P E C I F I C I T Y  C L O N E  I G  C L A S S  
W O R K I N G  
D I L U T I O N  
S O U R C E ∗  C O N J U G A T E  
CD13 5-390 mouse IgG1 4.5 μg/ml O. Majdic FITC, PE 
CD13 5-623 mouse IgG1 2.5 μg/ml O. Majdic FITC, PE 
CD14 M5E2 mouse IgG2a 5 μg/ml BD Biosciences purified 
CD14 TüK4 mouse IgG2a 4 μg/ml Caltag APC 
CD31 WM59 mouse IgG1 1 μg/ml Serotec FITC 
CD34 8G12 mouse IgG1 0.5 μg/ml BD Biosciences PE 
CD34 581 mouse IgG1 5 μg/ml BD Biosciences purified 
CD34 581 mouse IgG1 2 μg/ml Immunotech purified 
CD34 AC136 mouse IgG2a 1:100  Miltenyi APC, FITC 
CD45 2D1 mouse IgG1 0.5 μg/ml BD Biosciences FITC, purified 
CD45 HI30 mouse IgG1 1:100 BD Biosciences PE 
CD45 J33 mouse IgG1 1 μg/ml Immunotech APC 
CD90 5E10 mouse IgG1 1 μg/ml BD Biosciences PE 
CD90 F15-42-1 mouse IgG1 2 μg/ml Serotec purified 
CD117 YB5.B8 mouse IgG1 4 μg/ml BD Biosciences PE, purified 
CD133/1 AC133 mouse IgG1 1 μg/ml Miltenyi purified 
CD150 A12 mouse IgG1 5 μg/ml BioLegend PE 
CD150 A12 mouse IgG1 1 μg/ml BD Biosciences purified 
CD318 CUB1 mouse IgG2b 2 μg/ml BD Biosciences AF 647, PE 
CD318 CUB1 mouse IgG2b undiluted H. J. Bühring purified 
Keratin 14 polyclonal rabbit IgG 1 μg/ml Covance FITC 
PAL-E PAL-E mouse IgG2a 1:100 Fitzgerald purified 
Smooth Muscle Actin 1A4 mouse IgG2a 7 μg/ml Sigma FITC 
A B  S P E C I F I C I T Y  I G  C L A S S  
W O R K I N G  
D I L U T I O N  
S O U R C E  C O N J U G A T E  
Goat anti-mouse F(ab')2 IgG (H+L) 5 μg/ml Caltag FITC 
Goat anti-mouse F(ab')2 IgG (H+L) 10 μg/ml Invitrogen 
Alexa 546,  
Alexa 647 
Goat anti-mouse goat F(ab')2 IgG+IgM (H+L) 7 μg/ml Medac Biotin 
Streptavidin   2 μg/ml Amersham Texas Red 
N U C L E I C  A C I D  S T A I N I N G  
Dapi   1:4 Vectashield detection via UV light 
Sytox   1:106 Molecular Probes Green, Orange 
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8 . 1 5  P R E P A R A T I O N  O F  H U M A N  D E R M A L  C E L L S  
F O R  F A C S  A N A L Y S I S  
Sterilized foreskin was placed on 25% dispase (O/N, 4°C). After separating dermis from 
epidermis, dermis was cut into small pieces and digested in liberase (90 min, 37°C). 
Digested tissue was sifted through a steel mesh, and subsequently filtered through a cell 
strainer. Cells were washed in normal cell culture medium (RPMI 1640 medium was 
supplemented with 10% heat-inactivated FCS, 25 mM HEPES, 10 μg/ml gentamycin, 2 
mM L-glutamine, 0.1 mM non-essential amino acids, 1 mM sodium pyruvate, 50 μM 2-
ME, and 0.002% antibiotic-antimycotic), centrifuged and counted. 
For FACS analysis, dermal cells were diluted in 100 μl FACS buffer. Antibodies were 
added in the proper concentrations and incubated (30 min, ice). After centrifugation, 
supernatant was discarded and cells resuspended. 
For two and three-color analyses, dermal cells (5x105/sample) were resuspended in FACS 
buffer and incubated with APC-, FITC-, PE-conjugated mAbs directed against selected 
human antigens. To block non-specific binding of mAb, cells were incubated with 
adequate serum prior to the staining procedures. Specificity of staining was confirmed 
using isotype-matched control mAb. Dead cells were excluded by 7-AAD (1 µg/ml) 
uptake. To detect intracellular antigens, such as K14, dermal cells were permeabilized 
with Cytofix/Cytoperm (250 μl/ml; 24°C, 20 min). After washing with 0.1% saponin/PBS, 
cells were either stained with a non-conjugated or direct labeled mAb (30 min, 4°C). 
Non-conjugated mAb were visualized by a second-step reagent (30 min, 4°C). 
Appropriate isotype mAb were used as controls. After washing with 0.1% saponin/PBS, 
subsequent staining was performed as described above. The staining procedure was 
performed in microtubes (100 μl cells/sample). 
Fluorescence was measured with a FACSCalibur flow cytometer, and data were analyzed 
with Cell Quest software.  
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9  S U P P L E M E N T A L  D A T A  
T A B L E  6 .  A N A L Y Z E D  M U R I N E  O R G A N  S A M P L E S .  
S A M P L E  
#  
E X P E R I M E N T  O R G A N  
C E L L  T Y P E  
T R A N S P L A N T E D  
I S O L A T I O N  
O F …  
1 Exp 16.07.2003 / 19.04.2004 Spleen 
NB dermis 
DNA & RNA 
2 Exp 16.07.2003 / 19.04.2004 Thymus DNA & RNA 
3 Exp 16.07.2003 / 19.04.2004 Skin DNA & RNA 
4 B2 SP (neg. control) Spleen   DNA & RNA 
5 R2 SP (pos. control) Spleen   DNA & RNA 
6 Exp 28.01.2004 / 21.04.2004 Spleen 
CD45+ 
DNA & RNA 
7 Exp 28.01.2004 / 21.04.2004 BM DNA & RNA 
8 Exp 28.01.2004 / 21.04.2004 Skin DNA & RNA 
9 Exp 28.01.2004 / 21.04.2004 Lymph Node DNA & RNA 
10 Exp 11.02.2004 / 23.04.2004 Spleen (Sp B) 
CD34- 
DNA & RNA 
11 Exp 11.02.2004 / 23.04.2004 BM (BM B) DNA & RNA 
12 Exp 11.02.2004 / 23.04.2004 Skin (SK B) DNA & RNA 
13 Exp 11.02.2004 / 23.04.2004 Lymph Node (LN B) DNA & RNA 
14 B2 BM (neg. control) BM   DNA & RNA 
15 R2 BM (pos. control) BM   DNA & RNA 
16 Exp 11.02.2004 / 23.04.2004 Skin (Sk A) 
CD34+ 
RNA 
17 Exp 11.02.2004 / 23.04.2004 Spleen (Sp A) RNA 
18 Exp 11.02.2004 / 23.04.2004 Thymus (Th A) RNA 
19 Exp 11.02.2004 / 23.04.2004 Lymph Node (LN A) RNA 
20 Exp 11.02.2004 / 23.04.2004 BM (BM A) RNA 
21 Exp 11.02.2004 / 23.04.2004 Liver (L A) RNA 
22 Exp 13.08.2003 / 06.04.2004 Skin (SK A) 
CD90+ 
RNA 
23 Exp 13.08.2003 / 06.04.2004 Spleen (Sp A) RNA 
24 Exp 13.08.2003 / 06.04.2004 Thymus (Th A) RNA 
25 Exp 13.08.2003 / 06.04.2004 Lymph Node (LN A) RNA 
26 Exp 13.08.2003 / 06.04.2004 BM (BM A) RNA 
27 Exp 13.08.2003 / 06.04.2004 Liver (L A) RNA 
28 Exp 18.11.2003 / 02.04.2004 Skin (SK A) 
Lin- 
RNA 
29 Exp 18.11.2003 / 02.04.2004 Spleen (Sp A) RNA 
30 Exp 18.11.2003 / 02.04.2004 Thymus (Th A) RNA 
31 Exp 18.11.2003 / 02.04.2004 Lymph Node (LN A) RNA 
32 Exp 18.11.2003 / 02.04.2004 BM (BM A) RNA 
33 Exp 18.11.2003 / 02.04.2004 Liver (L A) RNA 
34 B2 L (neg. control) Liver   RNA 
35 R2 L (pos. Control) Liver   RNA 
36 Exp 13.08.2003/06.04.2004 Skin (SK B) 
CD90- 
RNA 
37 Exp 13.08.2003/06.04.2004 Spleen (Sp B) DNA & RNA 
38 Exp 13.08.2003/06.04.2004 Thymus (Th B) RNA 
39 Exp 13.08.2003/06.04.2004 Lymph Node (LN B) RNA 
40 Exp 13.08.2003/06.04.2004 BM (BM B) RNA 
41 Exp 13.08.2003/06.04.2004 Liver (L B) RNA 
42 Exp 13.05.2003/09.04.2004 Skin (SK A) 
NB dermis 
RNA 
43 Exp 13.05.2003/09.04.2004 Spleen (SP A) DNA & RNA 
44 Exp 13.05.2003/09.04.2004 Thymus (Th A) RNA 
45 Exp 13.05.2003/09.04.2004 Lymph Node (LN A) RNA 
46 Exp 13.05.2003/09.04.2004 BM (BM A) RNA 
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47 Exp 13.05.2003/09.04.2004 Liver (L A) RNA 
48 Exp 14.11.2003/13.04.2004 Skin 
adult dermis 
RNA 
49 Exp 14.11.2003/13.04.2004 Spleen DNA & RNA 
50 Exp 14.11.2003/13.04.2004 Thymus RNA 
51 Exp 14.11.2003/13.04.2004 Lymph Node RNA 
52 Exp 14.11.2003/13.04.2004 BM RNA 
53 Exp 14.11.2003/13.04.2004 Liver RNA 
54 Exp 21.04.2003/22.04.2004 Skin 
Lin- 
RNA 
55 Exp 21.04.2003/22.04.2004 Spleen DNA & RNA 
56 Exp 21.04.2003/22.04.2004 Thymus RNA 
57 Exp 21.04.2003/22.04.2004 Lymph Node RNA 
58 Exp 21.04.2003/22.04.2004 BM RNA 
59 Exp 21.04.2003/22.04.2004 Liver RNA 
60 Exp 21.01.2004/15.04.2004 Skin (SK A) 
Lin- 
RNA 
61 Exp 21.01.2004/15.04.2004 Spleen (SP A) DNA & RNA 
62 Exp 21.01.2004/15.04.2004 Thymus (Th A) RNA 
63 Exp 21.01.2004/15.04.2004 Lymph Node (LN A) RNA 
64 Exp 21.01.2004/15.04.2004 BM (BM A) RNA 
65 Exp 21.01.2004/15.04.2004 Liver (L A) RNA 
66 B2 SP (neg. control) Spleen   DNA & RNA 
67 R2 SP (pos. control) Spleen   DNA & RNA 
68 B2 L (neg. control) Liver   RNA 
69 R2 L (pos. Control) Liver   RNA 
70 Exp 16.07.2003/19.04.2004 Lymph Node 
NB dermis 
RNA 
71 Exp 16.07.2003/19.04.2004 BM RNA 
72 Exp 16.07.2003/19.04.2004 Liver RNA 
73 Exp 28.01.2004/21.04.2004 Thymus 
CD45+ 
RNA 
74 Exp 28.01.2004/21.04.2004 Liver RNA 
75 Exp 23.07.2003/09.04.2004 Skin (SK B) 
Lin- 
RNA 
76 Exp 23.07.2003/09.04.2004 Spleen (SP B) RNA 
77 Exp 23.07.2003/09.04.2004 Thymus (TH B) RNA 
78 Exp 23.07.2003/09.04.2004 Lymph Node (LN B) RNA 
79 Exp 23.07.2003/09.04.2004 BM (BM B) RNA 
80 Exp 23.07.2003/09.04.2004 Liver (L B) RNA 
81 Exp 07.05.2003/02.04.2004 Skin 
Lin- 
RNA 
82 Exp 07.05.2003/02.04.2004 Spleen RNA 
83 Exp 07.05.2003/02.04.2004 Thymus RNA 
84 Exp 07.05.2003/02.04.2004 Lymph Node RNA 
85 Exp 07.05.2003/02.04.2004 Bonde Marrow RNA 
86 Exp 07.05.2003/02.04.2004 Liver RNA 
87 Exp 11.02.2004 / 23.04.2004 Thymus (Th B) 
CD34- 
RNA 
88 Exp 11.02.2004 / 23.04.2004 Liver (L B) RNA 
89 Exp 16.07.2003/30.03.2004 Skin (SK C) 
NB demis 
RNA 
90 Exp 16.07.2003/30.03.2004 Spleen (SP C) RNA 
91 Exp 16.07.2003/30.03.2004 Thymus (TH C) RNA 
92 Exp 16.07.2003/30.03.2004 Lymph Node (LN C) RNA 
93 Exp 16.07.2003/30.03.2004 BM (BM C) RNA 
94 Exp 16.07.2003/30.03.2004 Liver (L C) RNA 
95 Exp 21.01.2004/15.04.2004 Skin (SK B) 
Lin- 
RNA 
96 Exp 21.01.2004/15.04.2004 Spleen (SP B) RNA 
97 Exp 21.01.2004/15.04.2004 Thymus (TH B) RNA 
98 Exp 21.01.2004/15.04.2004 Lymph Node (LN B) RNA 
99 Exp 21.01.2004/15.04.2004 BM (BM B) RNA 
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100 Exp 21.01.2004/15.04.2004 Liver (L B) RNA 
101 Exp 23.04.2003/16.03.2004 Skin 
adult dermis 
RNA 
102 Exp 23.04.2003/16.03.2004 Spleen RNA 
103 Exp 23.04.2003/16.03.2004 Thymus RNA 
104 Exp 23.04.2003/16.03.2004 Lymph Node RNA 
105 Exp 23.04.2003/16.03.2004 Bonde Marrow RNA 
106 Exp 23.04.2003/16.03.2004 Liver RNA 
107 Exp 18.11.2003 / 04.02.2004 Skin 
Lin- 
RNA 
108 Exp 18.11.2003 / 04.02.2004 Kidney RNA 
109 Exp 18.11.2003 / 04.02.2004 Thymus RNA 
110 Exp 18.11.2003 / 04.02.2004 Lymph Node RNA 
111 Exp 18.11.2003 / 04.02.2004 Bonde Marrow RNA 
112 Exp 18.11.2003 / 04.02.2004 Liver RNA 
113 Exp 10.09.2003/05.04.2004 Skin 
CD90+ 
RNA 
114 Exp 10.09.2003/05.04.2004 Spleen RNA 
115 Exp 10.09.2003/05.04.2004 Thymus RNA 
116 Exp 10.09.2003/05.04.2004 Lymph Node RNA 
117 Exp 10.09.2003/05.04.2004 Bonde Marrow RNA 
118 Exp 10.09.2003/05.04.2004 Liver RNA 
119 Exp 11.08.2003/18.03.2004 Skin (SK A) 
CD90- 
RNA 
120 Exp 11.08.2003/18.03.2004 Spleen (SP A) RNA 
121 Exp 11.08.2003/18.03.2004 Thymus (TH A) RNA 
122 Exp 11.08.2003/18.03.2004 Lymph Node (LN A) RNA 
123 Exp 11.08.2003/18.03.2004 BM (BM A) RNA 
124 Exp 11.08.2003/18.03.2004 Liver (L A) RNA 
125 Exp 29.04.2004 Skin 
Lin- 
RNA 
126 Exp 29.04.2004 Spleen RNA 
127 Exp 29.04.2004 Thymus RNA 
128 Exp 29.04.2004 BM RNA 
129 Exp 29.04.2004 Liver RNA 
130 Exp 11.08.2003/18.03.2004 Skin (SK B) 
CD90- 
RNA 
131 Exp 11.08.2003/18.03.2004 Spleen (SP B) DNA & RNA 
132 Exp 11.08.2003/18.03.2004 Thymus (TH B) RNA 
133 Exp 11.08.2003/18.03.2004 Lymph Node (LN B) RNA 
134 Exp 11.08.2003/18.03.2004 BM (BM B) RNA 
135 Exp 11.08.2003/18.03.2004 Liver (L B) RNA 
136 Exp 29.04.2004 Skin (SK C) 
Lin- 
RNA 
137 Exp 29.04.2005 Spleen (SP C) DNA & RNA 
138 Exp 29.04.2006 Thymus (TH C) RNA 
139 Exp 29.04.2007 Lymph Node (LN C) RNA 
140 Exp 29.04.2008 BM (BM C) RNA 
141 Exp 29.04.2009 Liver (L C) RNA 
142 Exp 29.04.2010 Skin (SK B) 
Lin- 
RNA 
143 Exp 29.04.2011 Spleen (SP B) DNA & RNA 
144 Exp 29.04.2012 Thymus (TH B) RNA 
145 Exp 29.04.2013 Lymph Node (LN B) RNA 
146 Exp 29.04.2014 BM (BM B) RNA 
147 Exp 29.04.2015 Liver (L B) RNA 
148 Exp 16.07.2003/30.03.2004 Skin (SK A) 
NB dermis 
RNA 
149 Exp 16.07.2003/30.03.2005 Spleen (SP A) DNA & RNA 
150 Exp 16.07.2003/30.03.2006 Thymus (TH A) RNA 
151 Exp 16.07.2003/30.03.2007 Lymph Node (LN A) RNA 
152 Exp 16.07.2003/30.03.2008 BM (BM A) RNA 
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153 Exp 16.07.2003/30.03.2009 Liver (L A) RNA 
154 Exp 16.07.2003/30.03.2010 Skin (SK B) 
NB dermis 
RNA 
155 Exp 16.07.2003/30.03.2011 Spleen (SP B) DNA & RNA 
156 Exp 16.07.2003/30.03.2012 Thymus (TH B) RNA 
157 Exp 16.07.2003/30.03.2013 Lymph Node (LN B) RNA 
158 Exp 16.07.2003/30.03.2014 BM (BM B) RNA 
159 Exp 16.07.2003/30.03.2015 Liver (L B) RNA 
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